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Tau is a microtubule binding protein typically found in neuronal axons. In an adult human brain, 
six isoforms of tau are generated by alternate mRNA splicing. These isoforms of tau differ from 
each other either based on the number of N-terminal inserts and/or the number of microtubule 
binding repeats. Tau is also closely related to a group of progressive neurodegenerative disorders 
together known as tauopathies. In these disorders, tau gets misfolded and its ability to stabilize 
microtubules gets compromised. Monomers of tau then begin to polymerize to form pathologic 
aggregates. These aggregates of tau get deposited in the patient’s brain and are closely related to 
neuronal dysfunction and death of neurons. Although the aggregation of tau is a central event for 
the majority of these tauopathies, the precise neuropathologic and clinical presentation differs 
between these diseases. The age of onset, area of brain affected, morphology of tau aggregates 
and the isoform of tau deposited as aggregates are a few of the distinguishing features between 
these tauopathies. The underlying mechanism of tau aggregation as well the mechanisms leading 
to these differences are not well understood. Before effective therapies can be devised to stop the 
process of tau aggregation, the mechanisms influencing this process need to be understood. One 
of the ways employed to gain a mechanistic understanding of this process is by using an in vitro 
aggregation model. In this model, an inducer molecule is used to generate aggregates of 
recombinantly produced tau and various mechanisms influencing the process of aggregation can 
be studied. This method has been successfully used to model aggregation of the longest isoform 
of tau called the 2N4R isoform, however the applicability of this methodology to isoforms 
missing one or more of the N-terminal inserts has proven to be challenging. In this study, we 
optimized the process of in vitro aggregation for these isoforms. We discovered that the major 
differences between the isoelectric points of the N-terminal region of these tau isoforms leads to 
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behavioral changes between these isoforms. This observation favors the notion that the isoforms 
of tau might also get disproportionately influenced by disease related mechanisms leading to 
their differential deposition as aggregates in certain tauopathies. On the contrary, the isoforms of 
tau have often been used interchangeably for the design of many studies. Using the optimized 
aggregation conditions, we investigated the effects of one such disease related changes in tau on 
various isoforms of tau. We performed a comparative study of autosomal dominant mutations in 
tau selected from three different regions and investigated their effects on the aggregation 
propensity and microtubule stabilizing properties of tau. We found subtle but significant 
differences in the effect of these mutations on various tau isoforms for all three selected mutants. 
Overall, these findings have opened up new avenues for the study of aggregation of various tau 
isoforms. They also helped us understand the differences between tau isoforms as well as how 
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Chapter I: Introduction 
1.1 Tau Overview 
The protein tau was first discovered in 1975 by Weingarten et al. and was noted as an important 
mediator of neuronal tubulin polymerization and stabilization of microtubules (1). Tau is 
predominantly expressed in neurons but can also be detected in glia and other non-neuronal cell 
types (2). Early research in the field of tau biology was focused on uncovering the relationship of 
tau with microtubules (3). About ten years from its initial discovery, in 1986, tau gained 
additional importance in the field of neurodegenerative disorders when several groups reported 
tau to be a component of the pathological intracellular neurofibrillary tangles (NFTs) or paired 
helical filaments (PHFs) found in Alzheimer’s disease (AD) (4-6). Further research involving the 
determination of the primary structure of the PHF core conclusively proved tau to the major 
constituent of PHFs (7). Since then, this neurofibrillary pathology composed by abnormal and 
aggregated tau protein is found to be closely associated with a group of dementias and movement 
disorders together termed as tauopathies (reviewed in (8)). This involvement of tau in numerous 
neurodegenerative diseases evoked interest in gaining a better understanding of the biochemical 
nature of tau, changes that may occur in tau during disease possibly leading up to its aggregation 
and how this aggregation could be toxic to the neurons. Despite the progress made, several 
questions pertaining to the cause of tau aggregation and the precise effects disease related 
mechanisms have on tau’s aggregation and microtubule stabilization propensity must be 




1.2 Tau gene structure and isoforms  
The human tau (MAPT) is a 134 kb gene located on chromosome 17 at position 17q21 and is 
made up of 16 exons (Figure 1) (9). The CNS forms of tau are generated by utilizing 11 of these 
exons (10). Exon 0 and 14 are transcribed but not translated. Exon 4a, 6 and 8 have only been 
reported in the peripheral tissue tau mRNA but not in the human brain. Exon 1, 4, 5, 7, 9, 11, 12 
and 13 are constitutive exons. Exon 2, 3 and 10 are alternatively spliced to generate six different 
CNS isoforms of tau ranging from 352 to 441 amino acids in length (10). Exon 9 through 12 
encode the highly conserved imperfect repeat sequences (denoted as R) responsible for tau’s 
ability to stabilize microtubules and thus the alternative mRNA splicing of exon 10 alters the 
number of microtubule stabilizing sequences in tau (11,12). Isoforms containing exon 10 are 
noted as 4R isoforms and isoforms lacking exon 10 are noted as 3R. There are approximately 
equal amounts of 3R and 4R tau in a normal brain (13,14). Alternative mRNA splicing of exon 2 
and 3 can alter the number of N-terminal inserts (denoted as N) present in tau. Inclusion of exon 
3 is dependent on inclusion of exon 2 and isoforms containing exon 3 without exon 2 have not 
been reported (10). Thus, the alternative mRNA splicing of exon 2 and 3 results in isoforms 
containing either both exon 2 and 3 (+2+3 or 2N), isoforms containing exon 2 but lacking exon 3 
(+2-3 or 1N) or isoforms lacking either of these inserts (-2-3 or 0N). 2N isoforms compose 
roughly 9%, 1N isoforms 54% and 0N isoforms 37% of cellular tau (13,15).   
Overall, the six isoforms resulting from alternative mRNA splicing of tau are designated as 
2N4R, 1N4R, 0N4R, 2N3R, 1N3R and 0N3R where the number preceding N corresponds to the 
number of N-terminal inserts and the number preceding R corresponds to the number of 
microtubule stabilizing repeats. Although, the relative expression levels of these isoforms are 
tightly regulated, the precise functional relevance of this regulation is not yet clear. The 
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expression of tau is also developmentally regulated. Fetal brain only expresses the 0N3R isoform 
of tau while all six isoforms are found in a normal adult human brain (16). Besides this, regional 
differences of tau expression and splicing within the brain have also been reported. For example, 
the granule cells of dentate gyrus only express 3R tau (17), the amount of 0N3R isoform was 
found to be lower in cerebellum (18) and the amount of 4R proteins was found to be higher in 
globus pallidus compared to other brain regions (19). 
The most well-established function of tau is to bind and stabilize microtubules. Tau is known to 
affect various aspects of microtubule assembly. Tau is capable of promoting microtubule 
nucleation, growth and bundling as well as greatly reducing the dynamic instability of 
microtubules (20-22). Interaction of tau with microtubules is important for maintaining axonal 
transport and cell shape (23). Several cell culture models have also indicated tau’s role in 
promoting neurite outgrowth and developing neuronal polarity (24-27). Tau is also known to 
influence the spacing of microtubules and thus control of the axonal diameter (28). This process 
of altering the microtubule spacing by tau is influenced by the size of the tau isoform (29). 
Bundling and spacing between microtubules can have great impact on transport of cargo and 
proteins along the microtubule tracks which in turn is particularly important for neurons due to 







Figure 1: Schematic representation of human tau gene and the six CNS isoforms generated by 
alternate mRNA splicing. Human tau gene is located on chromosome 17 at position 17q21 and is made 
up of 16 exons. Exon 0 and 14 are transcribed but not translated. Exons 4a, 6 and 8 are not found in the 
CNS isoforms of tau. Alternative mRNA splicing of exons 2, 3 and 10 generates the six tau isoforms 
found in the brain. Inclusion or exclusion of exons 2 and 3 generates isoforms with either 2, 1 or no acidic 
N-terminal inserts. Exon 9 through 12 encode for the MT binding repeats. Alternative mRNA splicing of 
exon 10 determines the number of MT stabilizing sequences in tau. Overall, the resulting isoforms are 
noted as 2N4R, 1N4R, 0N4R, 2N3R, 1N3R and 0N3R. The numbers preceding N and R denote the 










Figure 2: Schematic representation for the longest 2N4R isoform of tau. In the adult human brain, six 
isoforms of tau are generated by the alternate mRNA splicing of exon 2, 3 and 10 (represented as E2, E3 
and R2 here). The N-terminal region of tau is rich in acidic residues followed by a proline rich region. 
The C-terminal half of tau contains the microtubule stabilizing pseudo-repeats encoded by exon 9 through 
12 (represented as R1 through R4 here). The region preceding it projects off of the microtubules and is 
called the projection domain. The sequences important for aggregation are also contained within the 













1.3 Tau function 
In addition to tau’s interaction with microtubules, increasing evidence has suggested tau’s 
interaction with other cytoskeletal components. Tau has been found to be involved in remodeling 
of actin cytoskeleton (30-32). Tau also interacts with spectrin, plasma membrane and certain 
cellular components like mitochondria (33-35). These interactions have lead several to 
hypothesize that tau might be acting be as a mediator in establishing crosstalk between various 
cellular and cytoskeletal components. Further, Tau interacts with the SH3 domain of src-family 
non-receptor kinases such as fyn and fgr (36,37), phospholipase C-γ (PLC- γ) (38,39) and 
phosphatidylinositol bisphosphate (PIP2) (40) among several other cellular components that link 
tau as a signal transduction molecule with possible roles in maintenance of structural framework 
and neuronal polarity.   
Besides this, several other less explored functions of tau have been suggested. Recent evidence 
suggests tau’s possible role in neuronal activity, neurogenesis and synaptic plasticity (41-44). 
Tau has also been detected in the nucleus and nuclear tau seems to be playing a role in 
maintaining the integrity of DNA under normal and hyperthermic conditions (45,46). 
1.4 Tau structure and domains 
Tau has been classically described as a “natively unfolded” protein and biophysical studies have 
revealed very low secondary structure content (47,48). Consistent with the unfolded character of 
the protein, tau has an unusually high proportion of charged residues and a very low proportion 
of hydrophobic residues relative to other proteins, rendering tau to be an overall hydrophilic 
protein. The longest isoform of tau, 2N4R, contains 80 Serines or Threonines, 56 negatively 
charges residues, 58 positively charged residues and 8 aromatic residues. Tau is highly flexible, 
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resistant to heat or acid treatments and is very soluble in its native form (49). Although tau is 
overall a basic protein, the distribution of charges along the length of tau is another rather unique 
characteristic of tau. The first 120 residues are predominantly acidic followed by regions that 
have predominantly basic residues. This gives tau a dipole like characteristic. Further, there are 
several serine and threonine residues interspersed in between that can be phosphorylated to 
modulate charges along various regions of tau. The unfolded, flexible nature of tau along with 
the asymmetric distribution of charges are important properties that allow tau to bind to 
microtubules and several other partners. 
 
Based on the distribution of amino acids as well as functional roles, tau molecules can be 
subdivided into two major domains: the C-terminal microtubule binding domain and the N-
terminal projection domain (Figure 2). The microtubule binding domain contains 3 or 4 
imperfect repeats (R1-R4), encoded by exon 9 through 12, responsible for tau’s interaction with 
microtubules (11,12). Microtubule stabilization is achieved using an array of sites distributed 
within the 18 residue imperfect repeats (Figure 3) (50). These repeat regions are surrounded by 
13 or 14 residue flanking regions which are also needed for tau’s interaction with microtubules. 
4R tau has an additional microtubule stabilizing repeat (encoded by exon 10) than the 3R tau. 
Further, the inter-repeat region between R1 and R2, particularly the peptide 274KVQIINKK281, 
has been found to be the most potent in inducing microtubule assembly (11,22). This region is 
only present in the 4R isoforms. Because of these differences, 4R isoforms have a higher binding 
affinity than the 3R tau (51,52). Electrostatic interactions play an important role in mediating the 
interaction between tau and tubulin (53). The microtubule-binding repeat (MTBR) of tau has 
several positively charges lysines that are involved in tau’s interaction with the acidic surface of 
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the microtubules (54). Charge altering post-translational modifications like phosphorylation 
within and around the repeat region are known to modulate tau’s interaction with microtubules 
(55-57). While the MTBR region of tau engages in interactions with tubulin, the N-terminus of 
tau is known to project away from the surface of the microtubules and hence is called the 
projection domain (20). Although this region does not directly contribute in binding of tau with 
microtubules, it can influence microtubule organization and dynamics of tau’s microtubule 
binding indirectly. One major impact of this region is affecting the spacing between microtubules 
(28,29). Alternative mRNA splicing in the N-terminal region can alter the number of N-terminal 
inserts and thus can generate tau with varying projection domain lengths which may alter the 
spacing between microtubules and axonal diameter. In line with this, peripheral neurons have a 
large axonal diameter. Peripheral neurons express an isoform of tau (also called “big tau”) with 
an additional very long exon 4a (9,58). Apart from influencing the spacing, N-terminally 
truncated forms of tau also show altered microtubule interactions (59). Further, residue 2-18 of 
tau also called the PAD domain (Phosphatase-activating domain) is involved in a signaling 
cascade known to disrupt anterograde fast axonal transport in neurons (60).  Other than the 
indirect influence of this region on tau’s microtubule stabilization, the precise role for this region 
is not yet known. It has been proposed that tau’s interaction with the plasma membrane is also 
mediated by its N-terminal region (34).  
The region of projection domain preceding the microtubule stabilizing domain is rich in proline 
residues and is called the proline-rich region. This region of tau is involved in several signaling 
cascades. It has seven different PXXP motifs that provide recognition sites for several proteins 
like the Src family kinases like fyn and fgr (36). The interaction between tau and fyn has 
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proposed roles in mediating Aβ induced excitotoxicity (37). Additionally, the proline rich region 
and its phosphorylation state influences tau’s interaction with microtubules (57,61).  
Although tau is a natively unfolded protein with little to no secondary structure, recent 
biophysical data has revealed the existence of a global fold in tau in which various domains of 
tau engage in long-range interactions through its differently charged domains. This conformation 
of tau is called the “hairpin” or “paperclip” conformation in which both the N-terminal and C-
terminal regions of tau fold over to interact with each other as well as the microtubule stabilizing 
region of tau and thus bringing the termini closer to each other (Figure 4) (62). This structure of 
tau has been proposed to be affected by both physiological mechanisms like MT binding and 














Figure 3: Microtubule binding repeat region of tau. The residues in green form the pseudo-repeat 
region with MT binding sequences. The residues on the right side of the vertical line represent the 
residues before and after the MT binding regions as well as the residues from the inter-repeat regions. 












                      
 
Figure 4: The global hairpin structure of tau. In the global hairpin also known as the “paperclip” 
conformation of tau, the N and C termini fold over to interact with the each other as well the interior of 












1.5 Tau in pathology 
Tau is involved in pathogenesis of a wide spectrum of neurodegenerative disorders collectively 
termed as tauopathies. A common feature of these tauopathies is the accumulation of 
intracellular filamentous aggregates of hyperphosphorylated tau.  Despite intense investigation, 
the precise mechanism of tau mediated toxicity in these diseases remains elusive. In these 
disorders, due to possible alterations in tau like abnormal post-translational modifications or 
mechanisms promoting conformational changes in tau, tau loses its ability to effectively stabilize 
microtubules (65). Tau’s inability to stabilize microtubules can lead to destabilization of 
microtubule network and cytoskeletal changes. The resulting unbound tau can then associate 
with each other to form insoluble and potentially toxic aggregates. Therefore, both loss of 
function and toxic gain of function have been implicated. Besides this, other mechanisms like tau 
mis-localization or direct toxicity of misfolded monomer tau are also being investigated.   
There are arguments both supporting and opposing the loss of function hypothesis. Tau knockout 
mice only display minor cytoskeletal changes and lack any major abnormalities (28). However, 
recent evidence suggests behavioral alterations and brain atrophy in tau knockout mice even 
though tau’s microtubule stabilizing function can partly be compensated by other microtubule 
associated proteins (MAPs) (66). A better understanding of the loss of function mechanism will 
be achieved as novel possible roles of tau in processes like neurogenesis, synaptic plasticity, 
neuronal activity get investigated.  
Several arguments can be made in support of toxic gain of function hypothesis. The regional 
distribution of tau aggregates correlates with the severity of cognitive impairment in Alzheimer’s 
disease (67,68). A five to ten-fold overexpression of tau in transgenic mice leads to formation of 
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intracellular inclusions of tau and the presence of these aggregates correlates with axonal 
degeneration (69). Another strong argument in support of this hypothesis is the discovery of 
autosomal dominant mutations in tau several of which have been found to be pro-aggregation 
and are known to cause tauopathies (14,70,71). Some of these mutations are found in exon 10 of 
tau which is only present in the 4R isoforms of tau, and thus would only affect 20-25% of the tau 
molecules expressed with 75-80% of tau being normal, raising a strong possibility for a toxic 
gain of function rather than a loss of function. In order to understand the nature of the underlying 
cause and toxicity of tau aggregation, the biochemical nature of aggregation and mechanisms 
affecting aggregation need to be understood. 
1.6 Tau aggregation 
Aggregation of tau is a characteristic feature of several neurodegenerative disorders. The 
presence of aggregates of tau in almost all of the tauopathies strongly suggests that aggregates of 
tau might exert toxicity but very little is known about what causes tau to aggregate and how this 
aggregation could be toxic. Given the soluble and unfolded nature of native tau, its aggregation 
into an ordered filamentous structure seems counterintuitive. Biochemically, the paired helical 
filaments of tau (PHFs) have a highly ordered β-sheet rich core (72,73). There are two short 
hexapeptide motifs in the beginning of the second and third microtubule binding repeats of tau, 
called PHF6 and PHF6* respectively, that have a propensity to change into β-sheets and are 
thought to be the drivers of tau aggregation (74,75). The first of these sequences, PHF6, 
275VQIINK280, is located in the second microtubule binding repeat which is only present in the 
4R isoforms of tau. The second hexapeptide motif, 306VQIVYK311, is present in the third 
microtubule binding repeat and is therefore present in all six isoforms of tau. These regions of 
tau are made of a stretch of alternate polar and apolar amino acids known to favor beta sheet 
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formation in proteins. In-between are also present amino acids like prolines that break this 
pattern and are known to disfavor β-sheet formation (76). Mutations in these regions that favor 
β-sheet formation, like P301L, are known to be pro-aggregation (77,78). Conversely, in vitro 
designed substitutions of two prolines for isoleucines , I277P and I308P, residing within the 
PHF6 and PHF6* motifs make tau incapable of assembling into aggregates (79).  
In-vitro studies have demonstrated that the aggregation of tau proceeds by a nucleation-
elongation mechanism (80). Initially, tau monomers join to form oligomeric structures. These 
oligomeric structures have been observed in cases of Alzheimer’s disease and other tauopathies 
and just by themselves are proposed to be toxic. The oligomeric structures provide a nucleus for 
recruitment of more tau monomers and the smaller oligomeric aggregate elongates to form a 
large filamentous cross-beta structure (81). In the cross-beta structures, the beta sheet rich 
monomers of tau are stacked on top of each other through intermolecular interactions and the 
orientation of beta sheets is perpendicular to the longer axis of the filament. The core of these 
filaments is formed by the repeat region of tau and the unstructured N and C terminal portions of 
tau protrude out from the core and form a “fuzzy coat”, named so because of its fuzzy 
appearance next to the highly ordered core region of the filament (82). These filamentous 
aggregates often take the form of paired helical filaments (PHFs) that have a periodicity of about 
80 nm in AD (83). Apart from PHFs, tau aggregates in the form of straight filaments lacking 
periodicity have also been found in Alzheimer’s disease brains (84). As these fibrillar structures 
grow and continue to accumulate, they form larger inclusions which, in the case of AD, are 
called neurofibrillary tangles (NFTs). The exact morphology of aggregates and appearance of 
inclusions is dependent on the tauopathy and will be discussed in later sections. 
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Although nucleation-elongation seems to be the path followed in formation of pathological tau 
aggregates, several questions remained unanswered. It is not clear what triggers the aggregation 
of highly soluble tau in the first place. In vitro, tau aggregation can be triggered using 
polyanionic compounds possibly through a conformational change in tau (85). Induction of tau 
aggregation has also been reported by two proteins, FKBP4 and FKBP52, through possible 
conformational changes induced in tau by these proteins (86). But, neither the nature of the 
inducer in vivo or the nature of conformational change is precisely known. Since tau recovered 
from NFTs is known to be highly phosphorylated, initial research in the field has focused on 
examining the effects of post-translational modifications of tau in order to identify possible 
differences between soluble and insoluble forms of tau. 
1.7 Tau phosphorylation 
Phosphorylation is the most widely studied post-translational modification of tau due to its role 
in both physiology of tau as well as the suspected role in pathology. It is also the most commonly 
occurring tau post-translational modification. Phosphorylation of tau is widely accepted to be a 
mechanism for modulating tau’s interaction with microtubules under normal conditions (55). 
Phosphorylation of tau is tightly controlled by a balance of protein kinases and phosphatases. 
Kinases like glycogen synthase kinase 3 (GSK3), Cdk5, protein kinase A (PKA) (87-89) and 
phosphatases like phosphoprotein phosphatase 2A (PP2A) and PP-1 (90,91) are among the key 
players in modulating tau’s phosphorylation state. There are 85 different putative 
phosphorylation sites in tau. In terms of pathology, it is not clear whether hyperphosphorylation 
of tau plays a causative role or is just a by-product of the pathological changes occurring in the 
cells. Nonetheless, aggregated tau from patients and in transgenic mice is found to be 
hyperphosphorylated.  In normal brain, there is approximately 2 to 3 mole of phosphate found 
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per mole of tau but for tau extracted from AD brains, there can has as much as 5 to 9 mole of 
phosphate per mole of tau (92). Out of 85 potential phosphorylation sites, 28 are only found to be 
phosphorylated in AD brains compared to normal brain (reviewed in (93)). Abnormal tau 
phosphorylation is known to reduce microtubule binding. The impact of phosphorylation on 
aggregation of tau has been a matter of debate. Phosphorylation of tau precedes tau aggregation 
(94) though it is neither necessary nor sufficient on its own to drive tau aggregation in vitro . The 
effect of phosphorylation on tau aggregation has been difficult to understand partly due to the 
sheer number and combination of phosphorylation sites possible. To study the effect of 
phosphorylation in vitro in a more systematic manner, pseudo-phosphorylation has been utilized. 
Under this technique, serine and threonine residue are mutated to aspartate and glutamate using 
site-directed mutagenesis. These point mutations are made to mimic the size and charge of 
phosphorylated serine or threonine residues. Using this technique, it was found that pseudo-
phosphorylation reduces the mobility of tau on SDS-PAGE indicating a possible change a 
conformation of tau (95). Pseudo-phosphorylation was also found to have an impact on tau’s 
aggregation propensity in a manner dependent on the tau isoform. Even though phosphorylation 
of tau might be inducing a conformational change, its link with tau aggregation remains complex 
and is still a matter under investigation. 
1.8 Other post-translational modifications of tau 
Tau is known to undergo several other post-translational modifications like acetylation, nitration, 
glycosylation and oxidation among others (reviewed in (93)). The effect of these modifications 
of tau on its biochemical properties is not well understood. Acetylation is another tau 
modification that has gained attention in recent years. Lysine 280 has been recognized as a major 
site for tau acetylation.  A Drosophila transgenic model mimicking tau acetylation at site K280 
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exacerbated the toxicity observed in this model due to tau overexpression (96). Further, 
acetylation of tau seems to alter the phosphorylation state of tau in this model. Acetylation of tau 
is also suspected to have an impact on synaptic function and memory (97). Abnormal nitration of 
tau has also been detected in AD and other tauopathies. Nitration of tau reduces tau’s ability to 
bind microtubules as well as have an impact on aggregation of tau (98). The major effect of 
glycosylation on tau seems to be enhancing phosphorylation of tau by suppressing its 
dephosphorylation and thus glycosylation can augment the potential toxic effects of 
hyperphosphorylation of tau (99). Finally, oxidation of tau at C322 has also been detected in tau 
from AD brain. C322 is present in the third microtubule binding region and can affect the 
conformation and aggregation of tau (100).  
 
1.9 Tauopathies 
Although the mechanisms inducing conformational changes in tau or triggering its aggregation 
remain under investigation, dysfunction and aggregation of tau is unequivocally linked to a wide 
spectrum of progressive neurodegenerative disorders together known as tauopathies. These 
disorders are characterized by intracellular aggregates of tau, progressive degeneration and death 
of neurons. Despite these commonalities, these group of diseases are rather heterogenous. These 
diseases differ from each other in terms of area of brain affected, age of onset, morphology of tau 
aggregates observed in these, isoforms of tau affected and presence of other proteins in the 
aggregates (reviewed in (8)). A brief overview of few of these: Alzheimer’s disease (AD), 
Progressive Supranuclear Palsy (PSP), Corticobasal degeneration (CDB), Pick’s disease (PiD) 
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and Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 (FTDP-17) will be 
provided in the following section. 
1.9.1 Alzheimer’s disease 
Alzheimer’s disease is the most prevalent and widely-studied form of tauopathy. AD alone is the 
6th leading cause of death. Symptoms include but are not limited to memory loss and behavioral 
changes. The two major hallmarks of AD are intracellular neurofibrillary tangles composed by 
the tau protein and extracellular senile plaques primarily containing the β-amyloid (Aβ) peptide 
(101). The progression of the disease correlates well with the amount and spread of tau 
aggregation (68). The spread of pathology follows a consistent path and can be characterized by 
the sequential appearance of tau pathology in various brain regions: Braak stage I, tau pathology 
in transentorhinal/peripheral cortex; Braak stage II, CA1 region of the hippocampus; Braak stage 
III, limbic structures; Braak stage IV, amygdala, thalamus and claustrum; Braak stage V, 
isocortical areas; and lastly Braak stage VI, primary sensory, motor and visual regions. 
 The aggregated tau composing the neurofibrillary tangles in AD is polymerized predominantly 
into paired helical filaments. Although PHFs are more common in NFTs, straight filaments are 
also observed (102). Aggregates in AD contain all 6 isoforms of tau in roughly the same 
proportion as they are found in a normal brain (103). Other than tau, NFTs in AD also contain 
ubiquitin, RNA, GSK-3β, α-synuclein and apolipoprotein (104-108). Although no genetic 
polymorphisms are detected in tau in case of AD, 5% of the total AD cases are associated with 
genetic polymorphisms in other proteins, amyloid precursor protein (APP) or presenilins 1 and 2 
(109). These cases are early onset compared to the sporadic AD cases. Aβ pathology is also most 
likely upstream of tau pathology. For these reasons, role of Aβ in AD took the primary focus. 
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While Aβ pathology may be upstream of tau, there are compelling arguments in favor of tau’s 
role in AD. The location of NFTs correlates better with the regions of neurodegeneration and the 
observed clinical manifestations of the disease than the plaque pathology (67,110). In transgenic 
mice and cultured cells, Aβ requires the presence tau to exert any major toxic effects (63,111). 
On the other hand, toxic effects of tau can be seen independent of Aβ in cultured cells as well as 
in vivo models (112,113). The discovery of autosomal dominant mutations in tau in other 
tauopathies leading to tau aggregation and neurodegeneration supports tau’s role in 
neurodegenerative process (70,71,114). Finally, neurodegeneration is observed in several other 
sporadic tauopathies without the presence of Aβ (115).  
1.9.2 Progressive Supranuclear Palsy 
Progressive Suprabuclear Palsy (PSP) is described as a late-onset atypical parkinsonism. PSP 
cases mainly display movement defects and personality changes (116). Although dementia is 
also observed at later stages of the disease (117). Neuropathologically, cases of PSP display 
neuron loss, gliosis and NFT formation primarily in subcortical regions particularly in 
subthalamic nucleus, basal ganglia and brainstem but not as much on the frontal cortex as in AD 
(118). Ultrastructural examination also points towards major differences between AD and PSP. 
Instead of paired helical filaments like AD, NFTs in PSP are composed primarily by straight 
filaments. Straight filaments are also observed in the glial cells (119,120) . PSP is primarily a 4R 
tauopathy, that is, tau filaments mainly contain 4R isoforms of tau, although variable amounts of 
3R isoforms are also detected in some patients (121). Elevation in the levels of 4R isoforms 
mRNA is seen in the brainstem region of these patients and may contribute to the preferential 
deposition of 4R isoforms in PSP (122). 
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1.9.3 Corticobasal Degeneration 
 Corticobasal degeneration is a rare, sporadic, late onset and slow progressing neurodegenerative 
disorder. Some aspects of Corticobasal degeneration overlap with PSP (123). Like PSP, CBD is 
also a 4R tauopathy. However, it differs from PSP in terms of regions of brain affected. CBD 
pathology is observed in the cerebral cortex, substantia nigra and cerebellum (124). 
Ultrastructural analyses of CBD reveal both PHFs and straight filaments (125). Clinical 
symptoms include cognitive disturbances, difficulty with speech and motor dysfunction like 
rigidity and akinesia. 
1.9.4 Pick’s disease 
Pick’s disease is characterized by the presence of Pick bodies which are spherical inclusions 
containing both PHFs and straight filaments, however, filaments are wider than found in AD 
(126,127).  Aggregates are composed of almost exclusively the 3R isoforms of tau. Clinical 
symptoms include mood disturbances and language difficulties leading to mutism. Pick bodies 
are predominantly found in the granule cells of dentate gyrus, hippocampus and cortical areas 
(128).  
1.9.5 Frontotemporal Dementia with Parkinsonism Linked to Chromosome 17 
(FTDP-17) 
Frontotemporal Dementia with Parkinsonism linked to Chromosome 17 or FTDP-17 actually 
represents a group of clinically and pathologically heterogenous neurodegenerative disorders 
caused by autosomal dominant mutations in tau gene (129). The discovery of these mutations in 
late 1990’s established the causative role of tau in neurodegeneration. To date, more than 50 
different exonic and intronic mutations (Figure 5) have been identified to cause this early-onset 
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neurodegenerative tauopathy in approximately 150 different families across the globe (reviewed 
in (130)). Several of the mutations affect microtubule stabilizing propensity of tau or/and are 
pro-aggregation (77). Although, these mutations in themselves are rare, they have been widely 
used in the field of in vitro tau biology to understand the pathological changes that drive tau 
towards aggregation as well as the in vivo models to understand the neuropathology of 
tauopathies (131-133). Aggregation of tau is prevalent in cases of FTDP-17 but the clinical 
presentation and precise neuropathology can vary widely between families and sometimes within 
a same family (134-137). Age of onset can vary from the early 20s to late 70s with an average 
age of onset being 49 years (130). Symptoms often begin with psychiatric changes but progress 
to affect a wide range of brain functions. Some of the usual symptoms include behavioral 
changes, cognitive impairment, language difficulties, loss of executive functions and motor 
function. Due to the varied clinical symptoms and pathology, cases of FTDP-17 are often 
described by their similarities to other tauopathies like AD, Pick’s disease, PSP and CBD. 
Several FTDP-17, particularly the ones near exon 10 or in the non-coding regions around exon 
10, are known to affect the 3R to 4R tau isoform balance (138). 4R tau differs from the 3R tau in 
its ability to stabilize microtubules as well as its binding affinity for tubulin and may explain why 
the disruption of this ratio could be toxic. Further, biochemical analysis of aggregates from 
FTDP-17 cases reveal that some of the FTDP-17 mutations only cause certain isoforms of tau to 
be deposited in the brain, for example, in case of R5L and G389R, 4 of the six isoforms are 
found in the aggregates (139,140). Several FTDP-17, particularly the ones near exon 10 or in the 
non-coding regions around exon 10, are known to affect the 3R to 4R tau isoform balance (138). 
4R tau differs from the 3R tau in its ability to stabilize microtubules as well as its binding affinity 
for tubulin and may explain why the disruption of this ratio could be toxic. Further, biochemical 
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analysis of aggregates from FTDP-17 cases reveal that some of the FTDP-17 mutations only 
cause certain isoforms of tau to be deposited in the brain, for example, in case of R5L and 
G389R, 4 of the six isoforms are found in the aggregates (139,140). Altered splicing patterns of 
the N-terminus of tau have also been detected for one of the mutations, E342V, causing a higher 
expression of tau isoforms missing the N-terminal inserts (141). Since the role of the N-terminal 
region is not clearly understood, the expression levels of these exons haven’t been determined 










Figure 5: The known FTDP-17 mutations and their location on the tau gene. Intronic and 
exonic FTDP-17 mutations. Most of the mutations are present within and around the microtubule 
binding repeat region but mutations have also been discovered in the terminal exon 1 and 13. 
 








1.10 In vitro induction of tau aggregation 
In order to examine the effect of mechanisms influencing the process of tau aggregation or to 
find therapies that can impede the process of tau aggregation in vitro, aggregation of full length 
wild-type tau first needs to be achieved in a consistent manner. The highly soluble nature of 
native tau prevents it from aggregating on its own in a time-frame relevant for in vitro studies 
and requires the addition of an inducer molecule. Some of the common inducers of tau 
aggregation in vitro are polyanionic compounds like heparin, free fatty acids like arachidonic 
acid, planar aromatic dyes like congo red, and nucleic acids (74,142-144). Most of the inducer 
molecules known in vitro are negatively charged. The exact mechanism of aggregation induction 
by these molecules is not known but one of the suggested possibilities is that these negatively 
charged compounds mask the repulsive forces between the positively charged residues from the 
repeat regions of two tau monomers. Alternatively, some of the recent data suggests that these 
compounds cause PHF6 and PHF6* regions of tau to adopt an extended conformation which 
leads to loss of intramolecular interactions and favoring intermolecular interactions to initiate the 
fibrillization process (85).  
Although it is not known what inducers, if any, trigger the aggregation of tau in vivo, a few of 
these like fatty acids and nucleic acids are within the realm of possibility. Arachidonic acid 
(ARA) induction of tau aggregation can be achieved in the laboratory using physiologically 
relevant concentrations of tau. The aggregates obtained using this method resemble the straight 
filaments seen in AD and other tauopathies (145). They also bind to the dyes like Thioflavin S 
often used to stain the cross-beta structured amyloidal aggregates. Finally, these aggregates are 
also recognized by antibodies that recognize the autopsy-derived PHFs.  
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The above-mentioned characteristics of aggregates obtained by the arachidonic acid induction 
have made this a routinely utilized method to induce tau aggregation. This methodology has been 
successfully used to conduct various studies, like looking at the effect of post-translation 
modifications, tau mutations and testing aggregation inhibitors among several others. However, 
A great majority of these studies have been conducted using the 2N4R isoform of tau, largely 
because of the difficulties associated with reliably using this method for other isoforms of tau 
(discussed in Chapter 2). The focus of the next chapter has been to first, identify some of these 
difficulties. Second, try to understand the reasons behind these difficulties in an effort towards 
understanding the fundamental differences between tau isoforms which can not only help 
overcome the challenges associated with in vitro aggregation of tau isoforms but can also further 
our understanding about tau isoforms. Once that goal was achieved, the modified in vitro 
aggregation conditions could then be used to understand the effect of FTDP-17 mutations on 
aggregation of various isoforms of tau (Chapter 3).  In this chapter, a comparative study of three 
different FTDP-17 mutations was conducted to answer the question, whether the effect or the 
intensity of the effect of these mutations can differ between isoform. Further, to obtain a 
complete view of the effect of these mutations, along with aggregation, their effect on the normal 
















CHAPTER 2: Optimization of in vitro conditions to study the arachidonic acid 











Chapter 2: Optimization of in vitro conditions to study the arachidonic acid 
induction of 4R isoforms of tau 
2.1 Introduction 
The accumulation of filamentous aggregates of microtubule associated protein tau is a 
pathological hallmark of several neurodegenerative disorders including Alzheimer’s disease 
(AD) (4,146). In an adult human brain, six different isoforms of tau are generated by alternative 
splicing of exons 2, 3 and 10 from an mRNA encoded by a single gene (147,148). The C-
terminal half of these proteins contains imperfect repeat sequences of amino acids encoded by 
exons 9 through 12 (149). The pseudo-repeats contain motifs responsible for tau’s interaction 
with microtubules called microtubule-binding repeats (MTBR) (11,12). The second repeat 
(MTBR2) is encoded by exon 10 and thus its presence or absence categorizes tau into either four 
repeat (4R or 10+) or three repeat (3R or 10-) isoforms, respectively. Alternative mRNA splicing 
of N-terminal exons 2 and 3 can change the number of acidic N-terminal inserts present within 
tau and give rise to isoforms with either two N-terminal inserts (2N isoforms), one N-terminal 
insert encoded by exon 2 (1N isoforms), or isoforms without either N-terminal insert (0N 
isoforms). Therefore, the six tau isoforms are designated 2N4R, 1N4R, 0N4R, 2N3R, 1N3R, and 
0N3R (148). 
Expression of tau isoforms is both temporally and spatially regulated (16,150). Isoforms are also 
known to exist in a specific ratio in the brain and disruption of this balance is associated with 
tauopathies (70,122,151,152). The putative involvement of exon 10 in tau pathology has been 
extensively studied and its impact on tau pathology has been widely demonstrated (153,154). A 
number of studies have pointed out the differences between 3R and 4R tau and how a disruption 
of the 3R to 4R tau balance could impact pathology: 3R tau differs from 4R tau in its 
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stabilization of microtubules (155,156), its aggregation (95,157),  and its seeding of the 
aggregation of monomeric tau (158). Disruption of the balance of the 3R to 4R tau isoform ratio 
has also been shown to affect anterograde vs retrograde transport of APP (159).  However, the 
direct impact of exons 2 and 3 on tau pathology is less well understood. Recent evidence has 
established links between the inclusion or exclusion of the N-terminal inserts with increased 
pathology and disease (160-162), although the underlying mechanisms remain largely unclear. 
For example, the MAPT haplotype 2 resulting in higher levels of exon 3-containing transcripts of 
tau has been associated with reduced risk for tauopathies like progressive supranuclear palsy 
(PSP) and corticobasal degeneration (CBD) (163). A weak association between tau haplotype 
and increased risk for AD has been identified (164), as well as reports of altered tau isoform 
expression in some cases of AD (152). On a cellular level, the exogenous addition of Aβ42 
peptide has been shown to favor the exclusion of exon 2 and 3 in tau transcripts in vitro (165). 
Furthermore, altered expression of N-terminal variants of tau or unexpected patterns of their 
inclusion in aggregates have been identified in specific cases of frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17) and PSP (135,139,141). It is likely that the 
N-terminal exons can play a significant role in the underlying mechanisms leading to tau-
induced neurodegeneration and therefore warrants more in-depth investigation.  
In vitro model systems utilizing negatively charged species as the inducer of tau aggregation 
have been pivotal in gaining insights into the mechanisms resulting in tau aggregation and 
possible factors influencing its aggregation (166-168). One such model is the use of the 
polyunsaturated fatty acid arachidonic acid (ARA) to induce the aggregation of tau in vitro 
(169). Fatty acid induction of tau aggregation may be of particular interest due to its potential 
biological role in the neurodegenerative process. For example, fatty acid metabolism is altered in 
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pathology (170,171). A rise in lipid peroxidation products and increased concentration of free 
cytosolic polyunsaturated fatty acids has also been linked to several neurodegenerative disorders 
(172,173). Fatty acids are also the prime components of cellular membranes and tau filaments 
have been observed to be either associated with or potentially growing out of membranes of 
neurons (174). ARA induced in vitro polymerization of tau is a widely established protocol and 
has successfully been used to model tau aggregation in vitro in a variety of studies, including the 
effects of phosphorylation, truncation, nitration, and FTDP-17 associated mutations in tau 
(77,175-177). However, the bulk of the ARA-induced aggregation studies of tau in vitro have 
focused on the 2N4R isoform. This could be due in part to the difficulties associated with in vitro 
ARA-induction of the 1N and 0N isoforms. For example, it has been reported that tau isoforms 
lacking exons 2 and 3 (the 0N isoforms of tau) fail to elongate into fibrils in the presence of 
ARA in vitro and only form short oligomeric aggregates of tau (178). To better understand the 
effect of disease related changes on 0N and 1N isoforms of tau, there is a need for a more robust 
in vitro aggregation model system for these isoforms.  
We hypothesized that the change in the isoelectric points of the N-terminal projection domain 
(residues 1-243) that would result from the inclusion or exclusion of exons 2 and 3 was 
responsible for the differences previously observed in the in vitro ARA-induction of tau 
polymerization. We tested this hypothesis by altering the pH and ionic strength of both ARA-
induced polymerization conditions and filament fixation conditions. We found that under normal 
in vitro polymerization conditions, the filaments formed by 1N4R and 0N4R isoforms have a 
tendency to aggregate into larger clusters of filaments. The degree of clustering was closely 
related to the overall charge of the N-terminal region. In conclusion, we show that by increasing 
the ionic strength of the in vitro ARA-induction of tau aggregation, robust and reliable amounts 
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of aggregation of all three 4R isoforms can be obtained, opening new avenues for tau 
aggregation studies that have previously been hampered by these differences in isoform 
isoelectric points. 
 
2.2 Methods and Materials 
2.2.1 Protein expression and purification 
All wild-type 4R tau isoforms and corresponding pseudo-phosphorylated mutant proteins (7-
phos) were expressed and purified as previously described (95,179). For the 7-phos proteins, 
mutations were introduced using the Quikchange site-directed mutagenesis kit (Agilent cat. 
200523). The 7-phos proteins contained the following mutations (numbered according to the 
2N4R isoform) S199E, S202E, T205E, T231E, S235D, S396E and S404E. DNA for all wild-
type and mutant isoforms in the pT7C vector (with a 6X histidine tag on the N-terminus) were 
transformed into BL-21 cells. Proteins were expressed and purified using nickel affinity 
chromatography followed by size exclusion chromatography as described previously. Final 
elution of protein was in a 10 mM HEPES buffer pH 7.64. Protein concentrations were 
determined using the PierceTM BCA protein assay kit (Thermo Scientific cat. 23225) following 
the manufacturer’s protocol with BSA as a standard. 
2.2.2 Tau polymerization with Arachidonic acid:  
Proteins at the concentration of 2 µM were incubated with Arachidonic Acid (ARA) (Millipore 
cat. 181198-100MG) to a final concentration of 75 µM in the polymerization buffer containing 
NaCl, 10 mM HEPES pH 7.64, 0.1 mM EDTA, 5 mM DTT and 3.75% ethanol (vehicle for 
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ARA) for 24 hours at 25 °C. The standard final concentration of the NaCl in the tau 
polymerization reactions was 100 mM, but ranged from 100 mM to 250 mM dependent on the 
experiment (see Results). Control reactions (in absence of ARA) were treated the same way as 
polymerization reactions except ARA was replaced with ethanol carrier for these reactions. 
2.2.3 Fixation of tau filaments and Electron Microscopy 
Fixation: For experiments to determine the effect of pH (Fig 2, 4): Polymerization reactions 
performed at the standard conditions of salt (100 mM NaCl) and pH (7.64) were diluted 1:10 in a 
buffer of selected pH (dependent on the experiment) along with the fixative glutaraldehyde 
(Electron Microscopy Sciences cat. 16120) at a final concentration of 2%. Buffers used for 
dilution at specific pH were CAPS (pH 10), CHES (pH 8.7), HEPES (pH 7.64), MOPS (pH 6.8), 
MES (pH 6.1 or 6) and acetate (pH 5). All buffers were used at a 10 mM strength with 0.1 mM 
EDTA and 100 mM NaCl (same as polymerization conditions).  
For experiments looking at the effect of pH at higher ionic strength (Fig 3): Polymerization 
reactions set up at the standard conditions of salt (100 mM NaCl) and pH (7.64) were diluted 
1:10 in a fixation buffer that contained 200 mM NaCl instead of 100 mM at the pH values 
indicated in Fig 3. 
For rest of the experiments (Fig 1, 5 and 7): Polymerization reactions were set up and diluted 
1:10 for fixation in 10 mM HEPES buffer pH 7.64 with 0.1 mM EDTA. The concentration of 
NaCl in the fixation buffer was identical to the buffer utilized for polymerization. 
After a 5-minute fixation at chosen conditions, samples were deposited on a formvar coated 
copper grid (Electron Microscopy Sciences cat. FCF-300CU) and stained with 2% uranyl acetate 
according to the previously published protocol (95).  Briefly, 10 μL of diluted and fixed 
polymerization reactions are pipetted onto a piece of parafilm. EM grids are placed on top of the 
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drop where they float for 1 minute. The grid is then blotted on filter paper, placed on a drop of 
water, blotted with filter paper, placed on a drop of 2% uranyl acetate, and blotted dry. All drops 
are 10 μL pipetted onto parafilm. The grid is then placed on another drop of 2% uranyl acetate 
and floated for 1 minute, and blotted dry for a final time. To ensure consistency between grids, 
fixation times are not allowed to exceed 15 minutes. Care should be taken handling 
glutaraldehyde and uranyl acetate. 
Electron Microscopy data collection: FEI TECNAI F20 XT field emission electron microscope 
(Hillsboro, OR) was used to examine the grids at a magnification of 3600x. Images were 
captured with the Gatan Digital Micrograph imaging system. Two different methods were 
employed to collect images: i) A Random selection method was utilized to minimize user bias. 
Under this method, five different areas of a grid were selected at random and images were 
captured. ii) A Search method was utilized to locate the less frequently encountered clusters of 
filaments. Here, the grid was searched until filament clusters were found and then images were 
captured. In general, five images are collected per grid. 
2.2.4 Charge predictions 
PROTEIN CALCULATOR v3.4 by Scripps Research Institute (http://protcalc.sourceforge.net/) 
was used to calculate the charges of N-terminal projection domain of 4R tau isoforms at several 
pH values. 
2.2.5 Thioflavin S fluorescence 
Thioflavin S (ThioS) (Sigma cat. T1892) was dissolved in MilliQ water at a concentration of 
0.224 mg/ml followed by filtration through a 0.22 micron filter. The ThioS solution was 
protected from light, prepared and used the same day. 150 µL of polymerization reactions were 
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transferred to a 96 well, flat bottom, white plate. 6 µL of ThioS solution was added to each well. 
The plate was shaken for 30 seconds followed by an incubation in the dark for 20 minutes. An 
excitation wavelength of 440 nm and an emission wavelength of 520 nm was used to record the 
shift in fluorescence resulting from ThioS binding to tau aggregates (145) using a Cary Eclipse 
fluorescence spectrophotometer (Varian Analytical Instruments, Walnut Creek, CA). Control 
reactions were used to determine the background fluorescence readings, and these values were 
subtracted from experimental wells. 
2.2.6 Right angle laser light scattering 
Polymerized protein solutions were transferred to 5 mm X 5 mm optical glass fluorometer 
cuvettes (Starna Cells, Atascadero, CA) and illuminated with a 12 mW solid state laser with a 
wavelength of 532 nm and operating at 7.6 mW (B&W Tek, Inc., Newark, DE). An image of the 
amount of light scattered was captured at the angle perpendicular to the path of the laser using a 
SONY XC-ST270 digital camera at an aperture setting of f5.6-8. Precise conditions should be 
optimized for each specific laser and camera setup. The images were analyzed using the 
histogram function of Adobe Photoshop CS5 Version 12.0 x32 to obtain a mean intensity 
indicative of the amount of light scattered. A fixed area (150 px by 15 px) was selected from 
each image and the mean density was recorded to represent the amount of light scattered for each 
condition. For calculating the pixel intensity across an image of scattered light, the plot profile 
function of ImageJ was used for a 180 pixels wide line. 
2.2.7 Kinetics of aggregation 
Although data are not presented in this report, these methods can be used to follow the kinetics 
of tau polymerization. For right angle laser light scattering, reactions are prepared in a 
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microcentrifuge tube and transferred to 5 mm X 5 mm optical glass fluorometer cuvettes before 
the addition of ARA. The amount of background scattering without ARA is measured and is 
used for background subtraction. ARA is added, gently mixed, and the amount of scattering is 
immediately captured (time zero). Images of scattered light are generally taken at 5, 10, 15, 20, 
25, and 30 minutes. Images are then taken at 45 and 60 minutes, followed by captures at 90, 120, 
180, 240, 300, and 360 minutes. ARA-induced polymerization reactions generally have reached 
an apparent steady state after 6 hours of incubation. Similarly, the kinetics of polymerization 
reactions can be followed using electron microscopy, although this method is much more 
involved and time-consuming. For this approach, reactions are performed in microcentrifuge 
tubes and then samples are taken at various time points, fixed, and EM grids are prepared for 
viewing and quantitation. We often reduce the number of time-points taken using this approach. 
In general we do not use ThioS for measuring kinetics of reactions because we have found that 
the addition of ThioS at the beginning of an ARA-induction of tau polymerization enhances the 
rate and amount of aggregation.   
 
2.3 Results 
2.3.1 Problems associated with arachidonic acid induced in vitro aggregation 
of shorter human tau isoforms 
ARA polymerization has been utilized in a number of studies targeted to investigate several 
aspects of tau aggregation in vitro (77,175-177). Using this technique, recombinantly expressed 
human tau isoforms are incubated in the presence of ARA in buffer containing 100 mM NaCl, 10 
mM HEPES pH 7.64, 5mM DTT and 0.1 mM EDTA. Under these conditions, 2N4R and 1N4R 
isoforms polymerize to form filamentous aggregates of tau reminiscent of straight fibrils 
36 
 
associated with Alzheimer’s disease and other tauopathies (Figure 6A). However, as previously 
reported, the 0N4R isoform fails to form straight filaments that are easily detectable by electron 
microscopy (Figure 6A). This result is confounded by the observation that ARA-induced 0N4R 
isoform polymerization reactions do have thioflavin S (ThioS) reactivity to an extent comparable 
with 2N4R and 1N4R isoforms (Figure 6B). There also seems to be an isoform-dependent 
difference in the appearance of laser light scattered by the filaments. The light scattered by the 
0N4R isoform often has a speckled appearance, with density missing from certain regions and 
oversaturated foci of scattered light in other areas, in contrast to the light scattered by the 2N4R 
and 1N4R isoforms which has a smoother, more uniform appearance (Figure 6C).  
The observed discrepancies between ThioS fluorescence and TEM data combined with the 
anomalous speckled appearance of the light scattered by the 0N4R isoform compared to the 
longer N-terminus variants, raised the possibility that the 0N4R tau filaments were 
conglomerating in solution. To investigate this possibility, we performed a thorough search of 
the microscopy grids for 0N4R isoform polymerization reactions rather than the standard 
operating procedure of randomly selecting areas of the grid for viewing to reduce observer bias 
in field selection.  Large, amorphous structures with heavy stain accumulations and with what 
appeared to be filaments protruding from their edges were observed in 0N4R polymerization 
reactions using the search method (Figure 6D). Clusters of tau filaments were also occasionally 
detected with thorough searching of EM grids for 1N4R polymerization reactions (Figure 6D), 
but these clusters were smaller and accumulated less uranyl acetate stain than those observed 
with 0N4R isoforms. Clusters of 2N4R isoform filaments could not be found under these 
experimental conditions even with extensive searching (Figure 6D). It is clear from this data that 
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the filaments formed from N-terminal variants of 4R isoforms have distinct solution 
characteristics from one another under these conditions.  
2.3.2 Differential electrostatics of the tau N-terminal projection domain and 
its role in filament clustering 
One fundamental difference between these isoforms is in their primary structure. Exon 2 and 
exon 3 each contain 29 amino acids and both regions are acidic in nature (below).  
 
At the standard working pH of 7.64, the N-terminal projection domain of the 2N4R (exon 2 and 
3), 1N4R (exon 2 only), and 0N4R (neither exon) isoforms are predicted to have an overall 
charge of -5.6, -1.7, and +5.3, respectively (Table 1). The N-terminal projection domain remains 
largely disordered and protrudes from the filament core formed by the MTBR region of tau 
(7,168,180,181). We therefore hypothesized that the clustering of 1N and 0N filaments is an 
outcome of the lower acidity and the overall charge of the N-terminal projection domain 
extending from the filament core.  
To test whether the decreasing acidity of the N-terminal projection domain leads to filament 
clustering through electrostatic interactions, we sought to counter this effect by either altering the 
pH or increasing the ionic strength of the solution containing tau filaments. Unlike what is 
predicted for the standard pH of 7.64, all three isoforms would have positively charged 
projection domains at a pH of 6.0, and all three isoforms would have negatively charged 
projection domains at a pH of 10.0 (Table 1). 
       -       --  --   -  - +     -   
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We first investigated the effects of pH on tau filament clustering by varying pH at the time of 
fixation. Polymerization reactions were performed as previously described using standard 
conditions of 2 μM protein and 75 μM ARA in 10 mM HEPES buffer, pH 7.64, and 100 mM 
NaCl. After 16 hours of incubation, samples were prepared for electron microscopy. Samples 
were fixed with 2% glutaraldehyde in buffers with different pH values chosen to alter the overall 
charge of the N-terminal projection domain: all positively charged (pH 6); standard conditions 
with different charges (pH 7.64); and all negatively charged (pH 10) (see Table 1). As predicted, 
buffer conditions for positively charged N-terminal projection domains (pH 6) results in filament 
clusters for all three 4R tau isoforms that could be located on EM grids with searching (Figure 
7A, 7G, 7M). Under these conditions, most EM fields of view selected at random had few 
filaments with only small particles of tau visible (Figure 7B, 7H, 7N). Fixation buffer conditions 
for negatively charged N-terminal projection domains (pH 10) resulted in even distributions of 
single strands of tau filaments on the electron microscopy grid for all three 4R isoforms, even 
with extensive searching (Figure 7E, 7F, 7K, 7L, 7Q, 7R). The 0N4R isoform, previously 
thought to only make small oligomeric aggregates with ARA (178), also showed filamentous tau 
aggregates when fixed at pH 10 (Figure 7Q, 7R), suggesting the possibility that the increase in 
pH causes clusters of filaments to dissociate during the fixation process.  
The modulation of filament clustering by changes in pH is consistent with the hypothesis that 
this phenomenon is mediated through electrostatic interactions. To further test this model, we 
sought to determine whether filament clustering observed under standard polymerization 
conditions could be disrupted with increased ionic strength. Tau aggregation reactions were 
again performed under standard conditions of pH 7.64 and 100 mM NaCl. Tau filaments were 
subsequently diluted in buffers containing higher amount of salt (200 mM) before glutaraldehyde 
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fixation in buffers with the same low (6), standard (7.64), and high (10) pH values examined 
above. Increased ionic strength of fixation buffers drastically decreased filament clustering 
(Figure 8). For example, the clustering of 0N4R filaments was essentially eliminated when the 
filaments were fixed at pH 7.64 and 200 mM NaCl (compare Figure 7O-P and 8O-P).  The 
increased ionic strength also drastically reduced the amount of 2N4R isoform filament clustering 
observed at pH 6 (compare Figure 7A-B and 8A-B). Therefore, increased ionic strength reduced 
the degree of filament clustering in a manner that correlates with the degree of negative charges 
in the N-terminal projection domains.  
2.3.3 Change in the acidity of the projection domain of tau through pseudo-
phosphorylation impacts filament clustering 
The previous results indicate that the clustering of filaments is due to electrostatic interactions 
involving the N-terminal projection domain, and more negatively charged amino acids in this 
region reduce clustering of tau filaments. We tested this directly by comparing non-modified 
protein with “pseudo-phosphorylated” versions. Pseudo-phosphorylation involves the mutation 
of serines and threonines to aspartic or glutamic acids. We used proteins called 7-phos because 
they have 7 different phosphorylation-mimicking mutations. Five of these residues (S199E, 
S202E, T205E, T231E, and S235D) are located in the N-terminal projection domain and the 
other two (S396E and S404E) are in the C-terminal region.  
Due to the presence of additional acidic residues, the pH at which the projection domains of 
pseudo-phosphorylated proteins would become positively charged and thus potentially result in 
filament clustering are expected to be lower than their wild-type counterparts (Table 2). We 
compared all three 4R isoforms wild-type proteins with their pseudo-phosphorylated forms using 
ARA and standard buffer conditions of 100 mM NaCl and pH 7.64. The fixation conditions were 
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chosen on an isoform-specific basis for high pH (both negatively charged), intermediate pH 
(different charges for N-terminal projection domains), and low pH (both positively charged) 
(Table 2).  
The filaments formed by all three pseudo-phosphorylated 4R isoforms required a lower pH than 
their corresponding wild-type proteins for clustering (Figure 9A-C). For example, an even 
distribution of filaments was observed for the 7-phos 1N4R protein at pH 6.8 (negatively 
charged), while the wild-type 1N4R filaments (positively charge at this pH) were completely 
clustered (Figure 9B). An even distribution of filaments was observed at pH 10 (both negatively 
charged) for both these proteins, while filaments of both wild-type and pseudo-phosphorylated 
proteins clustered at pH 6 (positively charged). These results indicate that the pseudo-
phosphorylation did not change the overall pattern of response of filament-filament interaction to 
changing pH, but rather changed the pH at which filaments clustered. Conditions that result in a 
positively charged N-terminal projection domain resulted in filament clustering, and conditions 
that result in a negatively charged N-terminal projection domain reduced filament clustering as 
demonstrated by even distributions of filaments on the EM grid.  
2.3.4 Effect of polymerization buffer salt concentration on total amount of 
aggregation of tau isoforms 
Because increasing the ionic strength of the fixation buffer or increasing its pH to 10 prevented 
the clustering of 1N4R and 0N4R filaments, we sought to determine whether employing these 
conditions during the polymerization reaction itself would have similar results.  
Increasing the pH for our tau polymerization reaction to pH 10 inhibited tau aggregation 
completely (data not shown). There could be several explanations for this outcome. One reason 
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could be that rise in pH could change the micellar state of ARA which in turn can alter its ability 
to cause tau aggregation. Another possible reason could be that a rise in pH may alter the 
conformation of tau and render it incapable of aggregation.  
We sought to determine whether increasing the ionic strength during polymerization would 
eliminate the clustering without compromising the total amount of aggregation of 4R tau 
isoforms. ARA-induced polymerization reactions were performed using pH 7.64 and 200 mM 
NaCl instead of 100 mM NaCl. Under these conditions, the filaments for all three isoforms were 
evenly distributed on the grid when fields were selected randomly. Clusters of filaments were not 
detected for any of the three isoforms even with extensive searching (Figure 10A). Furthermore, 
laser light scattered by the filaments assembled at 200 mM NaCl for 0N4R tau also had a smooth 
appearance (Figure 10B) unlike the speckled appearance observed at 100 mM NaCl (compare 
Figure 6C with Figure 10B).  
To compare the overall levels of tau polymerization with increasing ionic strength, 2 µM protein 
was incubated with 75 µM ARA for 24 hours at pH 7.64 and NaCl ranging from 100 mM to 250 
mM. At the end of the incubation period, the extent of polymerization was measured by two 
different techniques, a laser light scattering assay (Figure 11A) and a ThioS fluorescence assay 
(Figure 11B). None of these salt concentrations had any significant impact on the total amount of 
polymerization of any of the 4R isoforms of tau to a level detectable within the error of the 
techniques employed.  
Overall, increasing the ionic strength of the polymerization buffer or fixation buffer improved 
the utility of electron microscopy data for shorter tau isoforms, possibly by overcoming the 
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electrostatic interactions causing filament clustering (Figure 7,10) without inhibiting the process 
of tau aggregation to any significant extent (Figure 11).  
2.3.5 Utility of new aggregation conditions for in vitro aggregation studies of 
mixed tau isoforms 
Efforts to co-aggregate different 4R tau isoforms have proven to be difficult. Using the 
physiological ratio of 2N:1N:0N 4R isoforms of 9:54:37 (13,15), a final, total protein 
concentration of 2 µM was induced with 75 µM ARA at 100 mM NaCl (pH 7.64). These 
conditions resulted in clusters of aggregates that can be encountered frequently on the electron 
microscopy grid (Figure 12A). Increasing the ionic strength of polymerization reactions to 200 
mM NaCl eliminates the clustering of tau filaments completely (Figure 12A) without impacting 
the overall levels of polymerization when measured using laser light scattering (Figure 12B) or 
ThioS fluorescence (Figure 12C).  
It is not entirely known if various N-terminal variants of 4R tau isoforms can co-polymerize or 
seed the aggregation of other tau N-terminal variants. Unreliable polymerization of 0N4R tau 
isoform has previously hampered such studies. Here we present a model of co-polymerization of 
N-terminal variants of tau that can be employed to answer such questions in the future (Figure 
12). 
 
2.4 Discussion and Conclusions 
Aggregation of tau is a central event in the course of numerous neurodegenerative disorders 
(115). An in vitro model employing arachidonic acid as an inducer of tau aggregation has helped 
gain insight into the pathological mechanisms and factors influencing this event (77,166). While 
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this is true for the 2N4R isoform of tau, a reliable interpretation of data for the 1N4R and 0N4R 
isoforms of tau has been a challenging task (Figure 6) (178). In this study we have identified 
filament clustering of shorter isoforms of tau as a reason behind some of these complexities. Our 
data suggests that the electrostatic interactions involving the unstructured N-terminal projection 
domain of tau protruding from the filament core influences this clustering behavior.  
Specifically, we observed an inverse relationship between the acidity of tau N-terminal 
projection domain and the propensity of tau filaments to cluster. First, exclusion of the acidic N-
terminal inserts rendered the filaments formed by 0N and 1N isoforms of tau more sensitive to 
fluctuations in pH and salt and caused them to form clusters of filaments. Modulating the pH, 
and thus altering the overall charge carried by the N-terminal projection domain, indicated that a 
positively charged N-terminal projection domain results in filament clustering while this 
clustering behavior can be overcome by making the N-terminal projection domain negatively 
charged (Table 1 and Figure 7). Second, this hypothesis could be corroborated by utilizing 
mutations that raise the acidity of N-terminal projection domain (pseudo-phosphorylation). 
Pseudo-phosphorylated 4R tau isoforms require a lower pH to form clusters of filaments (Figure 
9).  
Interestingly, Wegmann et. al. observed that the adhesive properties of the “fuzzy coat”, formed 
by the unstructured regions of tau protruding from the filament core, change with pH and ionic 
strength of the environment surrounding tau filaments (181). Moreover, they observed that 
lowering the pH and thus making the fuzzy-coat overall positively charged enhanced adhesion to 
negatively charged particles. The reason behind a positively N-terminal projection domain 
leading to a tau filament clustering observed in our study is not yet clear but negatively charged 
species such as the fatty acid arachidonic acid (also present in the solution) could play a role in 
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facilitating the interactions between tau filaments, although more work would be needed to 
decipher their exact role. Nonetheless, this study sheds light into some of the processes that 
could affect the association of tau filaments with each other which may be of biological 
relevance. 
Association of filaments with each other is thought to be a fundamental process for formation of 
macroscopic pathological tau aggregates, such as neurofibrillary tangles. Here we observed that 
the unstructured N-terminal projection domain could be a driving factor behind such “tangle-
like” interactions. It can also be speculated that the electrolytic perturbances associated with 
aging and pathology (182) could be playing a role in the process. Moreover, it is important to 
note that such changes would have a differential effect on the N-terminal variants of tau. In 
addition to the effect of electrolytes and ions, we observed a phenomenon of tau filament 
clustering at low pH values. It is tempting to speculate that the low lysosomal pH could be 
implicated in affecting the properties of tau filaments and potentially altering tau filament-
filament association. 
Biological consequences of this charge driven association of tau filaments will need to be tested 
in future studies, nonetheless, the current study has immediate consequences in modeling of 
ARA induced aggregation of tau isoforms in vitro. We were able to overcome the clustering 
behavior of tau filaments by elevating the ionic strength in our tau polymerization protocol 
(Figure 10). This update in the current protocol of ARA-induced tau aggregation of isoforms 
could help devise future studies of various aspects of tau polymerization that may have isoform-
specific effects, like tau mutations, post-translational modifications, tau seeding and looking at 
the effect of previously identified tau aggregation inhibitors (183) on various tau isoforms. 
45 
 
pH 2N4R 1N4R 0N4R 
4.00 + 31.5 + 31.0 + 32.2 
4.50 + 21.3 + 22.1 + 25.6 
5.00 + 12.1 + 14.1 + 19.5 
5.50 + 6.7 + 9.4 + 15.9 
6.00 + 3.3 + 6.4 + 13.2 
6.50 - 0.2 + 3.2 + 10.2 
7.00 - 3.4 + 0.4 + 7.4 
7.50 - 5.3 - 1.4 + 5.6 
7.64 - 5.6 - 1.7 + 5.3 
8.00 - 6.4 - 2.4 + 4.6 
8.50 - 7.3 - 3.3 + 3.7 
9.00 - 8.9 - 4.8 + 2.3 
9.50 - 12.3 - 8.0 - 0.8 
10.00 - 18.1 - 13.6 - 6.1 
 
Table 1: Theoretical net charge carried by the projection domain (amino acids 1-243, along with the 
histidine purification tag) of various 4R tau N-terminal variants over a pH range. Experimentally studied 
pH values are indicated in bold. The cells colored in dark gray represent pH values at which the 
projection domain of each isoform is predicted to carry an overall positive charge. Light gray cells 













 Net Charge (Projection domain) 
Protein pH Wild-type 7-phos 
2N4R 
High (7.64) - 5.6 - 10.6 
Intermediate (6.1) + 2.6 - 2.3 
Low (5) + 12.1 + 8.1 
1N4R 
High (10) - 13.6 - 18.6 
Intermediate (6.8) + 1.4 - 3.6 
Low (6) + 6.4 + 1.5 
0N4R 
High (10) - 6.1 - 11.1 
Intermediate (8.7) + 3.3 - 1.7 
Low (6) + 13.2 + 8.3 
 
Table 2: Theoretical net charge carried by the projection domain (amino acids 1-243, along with the 
histidine purification tag) of various 4R tau wild-type and pseudo-phosphorylation (7-phos) N-terminal 
variants at three distict pH values (high, intermediate, low) chosen on an isoform-specific basis. The cells 
colored in dark gray represent pH values at which the projection domain of each isoform is predicted to 
carry an overall positive charge. Light gray cells represent the pH values at which the projection domain 















Figure 6: Discrepancies in ARA induced polymerization of 4R tau N-terminal variants. 2 µM protein was 
polymerized using 75 µM ARA overnight at 25° C under standard salt and pH conditions. A) electron 
micrographs of polymerized proteins obtained via a random selection criterion; B) extent of 
polymerization measured using ThioS fluorescence. Each bar represents data from 3 independent 
experiments ± SD; C) right-angle laser light scattering images (left) and the corresponding intensity of 
pixels across the width (right) for various 4R tau filaments; D) Electron micrographs obtained via 
searching the grids to obtain images of filament clusters, which are not evenly distributed. Scale bar is 1 




Figure 7: Effect of pH on filament clustering. Electron micrographs of 4R proteins polymerized using 2 
µM protein and 75 µM ARA under the standard conditions of 100 mM NaCl at pH 7.64 (verticle axis), 
with filament fixaton conditions represented on the horizontal axis. Two images for each working 
condition are presented. Images on the right side for each panel (Image B, D, F, H, J, L, N, P, R) were 
obtained using a random selection to minimize bias, and images on the left side for each panel (Image A, 
C, E, G, I, K, M, O, Q) were obtained after extensive searching to locate clusters of filaments. Scale bar in 












Figure 8: Countering the effect of pH by increasing ionic strength. Electron micrographs of 4R proteins 
polymerized using 2 µM protein and 75 µM ARA under the standard conditions of 100 mM NaCl at pH 
7.64 (verticle axis), with filament fixation conditions represented on the horizontal axis. Two images for 
each working condition are presented. Images on the right side for each panel (Image B, D, F, H, J, L, N, 
P, R) were obtained using a random selection to minimize bias, and images on the left side for each panel 
(Image A, C, E, G, I, K, M, O, Q) were obtained after extensive searching to locate clusters of filaments. 





Figure 9: Enhanced acidity of projection domain by pseudo-phosphorylation reduces sensitivity to 
clustering. Electron micrographs of A) 2N4R, B) 1N4R, C) 0N4R) proteins (wild-type and 7-phos 
variants) polymerized using 2 µM protein and 75 µM ARA under the standard conditions of 100 mM 
NaCl at pH 7.64. Fixation buffer contained 100 mM NaCl at all the indicated pH vaulues. Two images for 
each working condition are presented. Images on the right side of each panel (designated as R) were 
obtained using a random selection to minimize bias, images on the left side of each panel (designated as 
S) were obtained after extensive searching to locate clusters of filaments. Scale bar in upper right panel 




Figure 10: Polymerization at 200 mM NaCl eliminates clustering of filaments for all 4R tau isoforms and 
anomalous light scattering for 0N4R isoform. 4R proteins polymerized using 2 µM protein and 75 µM 
ARA. A) Electron micrographs of tau isoforms polymerized and fixed using a buffer containing 200 mM 
NaCl at pH 7.64. Two images for each working condition are presented. Images on the right side of each 
panel (designated as R) were obtained using a random selection to minimize bias, images on the left side 
of each panel (designated as S) were obtained after extensive searching to locate clusters of filaments. B) 
Right-angle laser light scattering images (top) and the corresponding intensity of pixels across the width 





Figure 11: Polymerization of 4R tau proteins at varying amounts of salt. 2 µM 4R proteins polymerized 
using 75 µM ARA in HEPES buffer pH 7.64 containing salt concentations ranging from 100 mM to 250 
mM overnight at 25° C. The final extent of polymerization was measured by A) ThioS fluorescence and 
B) right-angle laser light scattering (LLS). Each bar represents data from 3 independent experiments ± 
SD. One-way ANOVA analysis with Turkey’s multiple comparison test was used to determine the 
statistical significance of data obtained for each isoform at different salt concentrations for each of the 





Figure 12: Aggregation of mixture of 4R tau isoforms. 4R proteins at a molar ratio of 2N:1N:0N, 9:54:37 
polymerized using 2 µM total protein and 75 µM ARA at the salt and pH conditions indicated on the 
vertical axis, with filament fixaton conditions represented on the horizontal axis. Two images are 
presented to represent the uneven distribution of tau filaments resulting from clustering of tau filaments at 
100 mM NaCl; Extent of polymerization measured using laser light scattering (B) and ThioS fluorescence 
(C). Each bar represents data from 3 independent experiments ± SD. Student’s unpaired two-tailed t-test 
















CHAPTER 3: Effects of FTDP-17 mutants on aggregation and microtubule 












Chapter 3: Effects of FTDP-17 mutants on aggregation and microtubule 
stabilization properties of 4R isoforms of tau 
3.1 Introduction 
Tauopathies are a group of about thirty different clinically and biochemically heterogeneous 
neurodegenerative disorders together accounting for a large proportion of senile dementias. 
Although the precise nature of pathology and clinical presentation of these diseases varies on 
individual basis, symptoms include progressive cognitive decline, memory deficits, behavioral 
alterations and motor dysfunction among others. A unifying and prominent feature of these 
diseases is the deposition of filamentous aggregates of the microtubule-stabilizing protein tau in 
neurons and glia.   
In a normal adult human brain, tau exists in six distinct isoforms generated by alternate mRNA 
splicing of exons 2, 3 and 10 (10). Exon 10 encodes for one of the carboxy-terminal tandem 
repeats responsible for tau’s interaction with microtubules (11,12). Alternate splicing of this 
exon generates tau with either three microtubule-stabilizing repeats (3R-tau) or four microtubule-
stabilizing repeats (4R-tau). Further, inclusion or exclusion of amino-terminal acidic inserts 
encoded by exon 2 and 3 give rise to 0N, 1N or 2N tau within the 3R and 4R categories.  
Both familial and sporadic forms of tauopathies have been demonstrated to have a characteristic 
pattern of tau isoform deposition in the brain and this pattern has often been used as one of the 
defining features to classify a tauopathy (reviewed in (115)). Across the spectrum of these 
tauopathies, the mutations associated with the familial form of tauopathies also known as the 
FTDP-17 (Fronto Temporal Dementia and Parkinsonism linked to chromosome 17) have been of 
interest to understand the biochemical nature of tau and its aggregation. To date more than 50 
different exonic and intronic mutations in tau gene have been associated with FTDP-17 
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(130,184,185). A great majority of these mutations have been shown to either enhance tau’s 
aggregation propensity, alter tau’s interaction with microtubules or affect the splicing pattern of 
tau (77,114,186-190).  
FTDP-17 mutations have often been used as a tool to study tau aggregation and toxicity in a 
wide range of in vivo model systems (133,191-193). However, there has been a lack of consensus 
about the resulting effect of these mutations and the toxic species of tau in these models (194-
201). While epigenetic differences could explain this lack of consensus to some extent, it has 
been previously suggested that the heterogeneity seen in the patient’s phenotype and in vivo 
model systems could be a consequence of the observation that the FTDP-17 mutations are not 
just biochemically different from the wild-type but also differ markedly from each other (77). 
Further, isoforms of tau are known to be different from each other in terms of their ability to 
stabilize microtubules (155,202), their interaction with chaperone and other cellular proteins 
(203,204) and their subcellular localization (205). Thus, there could be minor conformational 
and functional differences between the tau isoforms in cells. Subsequently, it is also conceivable 
that if FTDP-17 mutations affect tau isoforms disproportionately, there would be differences in 
the observed phenotype based on the isoform most affected. Therefore, there is a need for a 
comparative study of FTDP-17 mutations in various tau isoforms to examine their effect on tau’s 
ability to aggregate as well as tau’s ability to stabilize microtubules. 
Here, in this study, we chose to examine the effect of three different FTDP-17 mutations on 
aggregation propensity and microtubule stabilizing ability of tau in vitro. To understand whether 
the location of the mutant within the primary sequence of tau could alter the degree of such 
possible effects, mutations from three separate regions of tau were selected. R5L and R406W 
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were selected as they occur in the distal N-terminal and C-terminal regions of tau respectively. 
For the MTBR mutation, we chose to examine the effect of P301L as this is one of the most 
commonly occurring FTDP-17 mutation and has also been widely employed to model tau 
aggregation in various in vivo model systems (191,195,206-208). P301L occurs in exon 10 of tau 
and thus only exists in the 4R isoforms. Therefore, we chose to examine the impact of all three 
FTDP-17 mutations in 4R isoforms of tau. 
We observed that the effect of a FTDP-17 mutation not only depends on the location of the 
mutation in tau’s primary sequence but the precise effect can be influenced by the number of N-
terminal inserts. We found subtle but significant differences in the effect of all three FTDP-17 
mutations on aggregation as well as microtubule stabilizing propensity of various 4R tau 
isoforms.  
 
3.2 Experimental Procedures 
3.2.1. Protein purification 
All three wild-type tau isoforms were cloned into the pT7c vector with an N-terminal poly-
histidine tag. QuickChange II site-directed mutagenesis kit was used to generate the R5L, P301L 
and R406W mutants in all three isoforms (Agilent Technologies). Proteins were expressed in E. 
coli and purified as described previously. Protein amounts were quantitated using the PierceTM 
BCA protein assay kit (Thermo Scientific).  
3.2.2. Aggregation induction using Arachidonic acid:  
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Wild-type and mutant proteins, at a concentration of 2 µM, were incubated with Arachidonic 
Acid (Millipore) to a final concentration of 75 µM in the polymerization buffer containing 200 
mM NaCl, 10 mM Hepes (pH 7.64), 0.1 mM EDTA, 5 mM DTT and 3.75% ethanol.  Reactions 
were kept at a constant temperature of 25 °C over-night before proceeding to assays for 
quantifying the extent of polymerization. 
3.2.3. Thioflavin S fluorescence assay 
Thioflavin S (ThS) (Sigma) stock solution was prepared at a concentration of 0.224 mg/ml in 
MilliQ water and filtered through a 0.22 micron filter before use. 150 µL of each aggregated tau 
reaction solution was transferred to a separate well of a flat bottom, 96 well, white plate. 6 µL of 
ThS stock solution was added to each sample. The plate was shaken for 30 seconds and then 
incubated in dark for 20 minutes. The resulting fluorescence shift was measured at an excitation 
wavelength of 440 nm and an emission wavelength of 520 nm using a Cary Eclipse fluorescence 
spectrophotometer (Varian Analytical Instruments, Walnut Creek, CA). The PMT detector 
voltage was set at 650 V. Control reactions were set up in absence of ARA and used to measure 
background florescence readings which were then subtracted from each polymerization sample. 
3.2.4. Right angle laser light scattering assay 
180 µL of polymerized sample was transferred to a 5 mm X 5 mm optical glass fluorometer 
cuvettes (Starna Cells, Atascadero, CA). A 12 mW solid state laser, with a wavelength of 532 nm 
and operating at 7.6 mW (B&W Tek, Inc., Newark, DE) was used to illuminate the polymerized 
protein sample. An image of the amount of light scattered was collected at the angle 
perpendicular to the angle of the laser beam using a SONY XC-ST270 digital camera at varying 
apertures from f4-f11. The images at aperture f5.6-8 were analyzed using the histogram function 
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of Adobe Photoshop CS5 Version 12.0 x32 to obtain a mean intensity corresponding to the 
amount of scattered light. 
3.2.5. Kinetics of ARA induced polymerization  
Right angle laser light scattering was used to monitor arachidonic acid induced kinetics of tau 
polymerization. Ratio of proteins and arachidonic acid were kept the same as previously 
described. Proteins diluted in the polymerization buffer were added to a 5 mm X 5 mm optical 
glass fluorometer cuvette. Arachidonic acid was added to the cuvette at time zero and images of 
the scattered light were captured through the time course of aggregation at an aperture setting of 
f5.6-8 until the polymerization reactions had reached a steady state. Images were again analyzed 
using the histogram function of Adobe Photoshop CS5 Version 12.0 x32. Data were fit to the 
Gompertz equation  
𝑦 = 𝑎𝑒−𝑒
−(𝑡−𝑡𝑖)/𝑏  
Here, a represents the maximum amount of polymerization. The lag time (the time between 
initiating the reaction till the time when polymerization was detectable is calculated at ti-b. The 
rate of polymerization, kapp, is found to be proportional to the inverse of b. Three individual data 
sets were fit to this equation to extract information about various parameters describing 
maximum polymerization, lag time and rate of polymerization. 
3.2.6. Transmission Electron Microscopy 
Polymerization reactions were diluted 1:10 in polymerization buffer with the same concentration 
of NaCl, EDTA and Hepes as the polymerization buffer, and the fixative glutaraldehyde to a 
final concentration of 2%. Samples are allowed to fix for 5 minutes and subsequently deposited 
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on a 300 mesh formvar coated copper grid and stained with uranyl acetate according to a 
previously published protocol (209). Briefly, the copper grid was placed on top of a drop of the 
fixed sample solution for 1 minute, followed by blotting on filter paper. The grid was then placed 
on top of a drop of water, botted dry, then placed on top of 2% uranyl acetate solution, blotted 
dry. For final staining with 2% uranyl acetate, the grid was left on top of the uranyl acetate 
solution for 1 minute. The grid was then blotted dry a final time before storing at room 
temperature. When ready to collect images, grids were loaded on a FEI TECNAI F20 XT field 
electron microscope (Hillsboro, OR). Images were collected at a magnification of 3600x using a 
Gatan Digital Micrograph system.  
3.2.7. Tubulin Polymerization assay 
A fluorescence based tubulin polymerization assay kit (Cytoskeleton Inc, Denver, CO) was 
utilized according to the manufacturer’s protocol to examine the effect of various test proteins on 
in vitro tubulin polymerization. All test proteins were used a final concentration of 1 μM. 
Tubulin at a concentration of 2 mg/ml in a buffer containing 80 mM PIPES pH 6.9, 2 mM 
MgCl2, 0.5 mM EGTA and 1 mM GTP was mixed with the test protein in a black, flat bottom, 
96 well plate. The final concentration of tubulin was 3.64 μM. A sample well containing 3 µM 
paclitaxel was used as a positive control. The fluorescence measurements were made with a 
FlexStation II Fluorometer (Molecular Devices Corporation, Sunnyvale , CA) using an excitation 
wavelength of 355 nm and an emission wavelength of 455 nm at a constant temperature of 37 
°C. The data were collected every 1 minute for a total of 60 minutes. A buffer and tubulin only 
sample was used to obtain the baseline fluorescence readings to be subtracted from each of the 
test condition. The resulting data were fit to the Gompertz growth curve to obtain various 
61 
 
parameters describing the growth curves of tubulin in a similar manner as kinetics of tau 
aggregation mentioned above. 
 
3.3 Results 
3.3.1. Total amount of aggregation  
Previously identified in vitro aggregation conditions using 2 μM protein and 75 μM arachidonic 
acid in the presence of 200 mM NaCl were utilized to determine the extent of aggregation of the 
3 selected FTDP-17 mutations in various 4R tau isoforms (209). Followed by an overnight 
incubation of proteins with the inducer, two orthogonal techniques, ThioflavinS (ThS) 
fluorescence assay (Figure 13A, 13C and 13E) and Laser light scattering (LLS) assay (Figure 
13B, 13D and 13F) were employed to assess the level of polymerized tau.  
The N-terminal mutation R5L affected the aggregation of tau in an isoform dependent manner 
(Figure 13A and 13B). 2N4R R5L tau polymerized to the same extent as the wild-type protein. A 
small decrease in the ThS fluorescence signal was observed for the R5L 1N isoform compared to 
the wild-type but the data did not reach significance for the LLS assay. R5L lead to a decrease in 
the total amount of polymerized tau for 0N isoform measured by both ThS fluorescence and 
LLS.  
The microtubule-stabilizing mutation P301L affected the level of polymerization irrespective of 
the isoform (Figure 13C and 13D). P301L tau polymerized to a higher extent compared to the 
corresponding wild-type protein in all three 4R isoforms. The C-terminal mutation R406W had 
no significant impact on the extent of aggregation for any of the isoforms under study (Figure 
13E and 13F).   
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Overall, the extent of aggregation of the N-terminal mutation R5L was found to be dependent on 
the number of N-terminal inserts present. The effects of the microtubule-stabilizing region 
mutation P301L and the C-terminal mutation R406W were less impacted by the number of N-
terminal inserts where all three isoforms were affected in the same manner. 
3.3.2. Kinetics of Aggregation 
Because tau mutations could conceptually change not only the overall amounts of aggregation, 
but also the rate of aggregation, we sought to determine whether the mutations had differential 
effects on the kinetics of polymerization in the backbones of the three tau isoforms. 
Polymerization for R5L, P301L, and R406W and their corresponding wild-type 0N4R, 1N4R, 
and 2N4R isoforms were monitored by LLS over time after the addition of ARA inducer.  
R5L did not have a significant effect on the kinetics of polymerization of the 2N4R or 1N4R 
isoforms (Figure 14A and 14B). However, there was a significant reduction in the maximum 
amount of polymerization of the 0N4R isoform (Figure 14C and 14D). Fits of the data to a 
Gompertz growth curve also indicated that the lag time before polymerization was significantly 
lower for 0N4R R5L compared to the 0N4R WT (Figure 14E), although there was no significant 
difference in the apparent rate of polymerization for any of the R5L isoforms compared to their 
wild-type counterparts (Figure 14F). 
The P301L mutation significantly influenced the kinetics of polymerization for each of the three 
4R isoforms (Figure 15). All three P301L isoform variants had increased levels of 
polymerization (Figures 15A-D). An increase in the lag time before polymerization was 
observed for all the 4R isoforms with P301L mutation compared to the WT (Figures 15A-C, 
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15E). Only the 2N4R P301L variant had a significant impact on the apparent rate of 
polymerization, causing a small decrease in kapp (Figure 15F). 
The R406W mutation did not have a significant impact on the overall amount of polymerization 
for any of the 4R isoforms (Figure 16 A-D). With 2N and 0N isoforms, a decrease in the lag time 
before polymerization was observed (Figure 16E), while only 1N4R isoform had a significant 
change in the apparent rate of polymerization with the R406W mutation (Figure 16F). 
Therefore, all three mutants in the study showed subtle differences in their effect on various 
parameters of polymerization kinetics. R5L primarily only had significant effects on the 0N4R 
isoform, P301L had significant effects on all three isoforms in terms of overall amount and lag 
time of polymerization along with a slight decrease in the apparent rate of 2N polymerization, 
and R406W only affected the lag time of polymerization in the 2N and 0N isoforms while the 
rate of polymerization was only influenced for the 1N4R isoform with R406W. 
3.3.3. Morphology of Aggregates 
Samples of polymerization reactions were prepared for viewing by electron microscope to 
determine whether the FTDP-17 mutations had any effects on the morphology of the filaments 
formed and whether any observed effects were different in the backbones of the 2N, 1N, and 0N 
isoforms. All isoforms and FTDP-17 variants formed filaments reminiscent of straight filaments 
from AD, which is characteristic of ARA-induced tau filaments (Figure 17). Upon quantitative 
analysis of the images, some differences between the FTDP-17 mutations in the isoforms 
become apparent. While quantitative electron microscopy is a useful tool in assessing filament 
morphology, care should be taken in reaching conclusions due to several important caveats: we 
are limited by only being able to view those filaments that adhered to the EM grid; there is 
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uncertainty whether the isoforms and/or FTDP-17 variants might adhere to the grid differently; 
adherence to the grid might potentially affect filament lengths (through breakage); the stain used 
for contrast might potentially distort actual filament lengths and might also be different for the 
variants; and the number of filaments analyzed per condition (~ 400-900 filaments) is small 
compared to the total filament population. Keeping these caveats in mind, an analysis of the 
frequency distribution of filament lengths reveals that all tau variants in 2N, 1N, and 0N 
isoforms have relatively exponential frequency distributions (Figure 18 A-C). It is also clear that 
the P301L isoform has a different distribution of filament lengths with fewer filaments <50 nm 
and proportionately more filaments longer than 50 nm for all three isoforms. This is consistent 
with the observation that P301L has a greater impact on the kinetics of polymerization than R5L 
or R406W in all three isoforms (Figure 14, 15, 16). When the total amount of polymerization, the 
number of filaments formed, and the average length of filaments is considered, only P301L has a 
significant effect on the 2N4R isoform, with significantly fewer, but significantly longer 
filaments (Figure 19 A-C). This is consistent with the observation of an increased lag time of 
polymerization kinetics for P301L in 2N4R (Figure 15E), while R5L and R406W did not 
significantly alter the kinetics of 2N4R polymerization (Figure 14, 16).  For 1N4R variants, 
P301L did have a significant increase in the total amount of polymerization (Figure 19D), and 
significant decrease in the number of filaments (Figure 19E), and a significant increase in the 
length of filaments (Figure 19F). R5L did not significantly alter 1N4R filament morphology, 
while R406W had a significant increase in the number of filaments formed (Figure 19E). These 
observations are consistent with the kinetics data of 1N4R polymerization that showed 
significant alterations to 1N4R polymerization by P301L and R406W, but not R5L (Figure 14, 
15, 16). All three variants altered the kinetics of 0N4R polymerization and all three variants also 
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affected the resulting filament morphologies. R5L had a significant reduction in total 
polymerization while P301L had a significant increase in total 0N4R polymerization (Figure 
19G). P301L had a significant decrease in the number of 0N4R filaments formed (Figure 19H). 
R5L and R406W resulted in significantly shorter 0N4R filaments, while P301L resulted in 
significantly longer 0N4R filaments (Figure 19I). Taken together, these results are broadly 
consistent with the kinetic analysis of tau aggregation in that only P301L had significant effects 
on filament numbers and length distribution in the 2N4R isoform; P301L and R406W, but not 
R5L, had significant effects of filament morphology in the 1N4R isoform; and all three variants 
significantly affected filament morphology in the 0N4R backbone. 
3.3.4. MT Assembly 
We further sought to determine if the effect of mutations on the normal functioning of tau could 
also depend on the isoform backbone. A fluorescence based MT assembly assay was utilized to 
monitor tubulin polymerization in the presence of tau mutant and wild-type proteins. The 
resulting data was fit to the Gompertz curve to understand and compare the possible defects in 
MT stabilization.  
Both R5L 2N4R and R5L 1N4R had no significant impact on the tubulin polymerization. R5L 
2N4R and R5L 1N4R induced polymerization of tubulin to the same extent, at the similar rate 
and lag times as the corresponding wild-types (Figure 20 A, B, D, E, F). In contrast, R5L 0N4R 
showed compromised microtubule assembly. For R5L 0N4R, overall tubulin polymerization 
extent was lowered, polymerization occurred at a lower rate and the lag time observed before the 
initiation of tubulin polymerization was longer (Figure 20 C, D, E, F).  
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P301L led to a decrease in the maximum tubulin polymerization and a reduced rate of 
polymerization in both 2N4R and 1N4R backbones (Figure 21 A, B, D, E). However, in the 
0N4R backbone, P301L only affected the rate of tubulin polymerization to a significant level 
(Figure 21 C, E). P301L did not significantly affect the lag time before initiation of 
polymerization in any of the 4R isoform backbones (Figure 21 F). 
R406W 2N4R induced tubulin polymerization at a lower rate than the wild-type (Figure 22 A, 
E), with no significant no impact on the maximum level of polymerization or the lag time before 
polymerization (Figure 22 D, F). R406W 1N4R lead to a reduction in maximum tubulin 
polymerization and it also induced the polymerization at a much lower rate than the wild-type 
1N4R protein (Figure 22 B, E). R406W 1N4R had no significant impact on the lag time before 
initiation of polymerization (Figure 22 F). R406W 0N4R increased the lag time before initiation 
of polymerization as well lowered the extent of tubulin polymerization without affecting the rate 
of tubulin polymerization (Figure 22 C, D, E, F). 
Overall, the effect of mutations on tubulin polymerization seemed to be significantly dependent 
on the isoform. R5L only affected the 0N4R isoform to a significant level. P301L affected all 
three isoforms but the extent of affect seems to correlate with the number of N-terminal inserts. 
For P301L, the isoform with both N-terminal inserts (2N4R) was affected the most and the 
isoform lacking any N-terminal inserts (0N4R) was affected the least.  R406W also altered the 
induction of tubulin polymerization of all three isoforms to varying degrees with the precise 






Tauopathies are a diverse group of neurodegenerative disorders characterized by dysfunction and 
aggregation of protein tau. Although the involvement of tau in pathology of these diseases has 
been unequivocally demonstrated, the underlying cause of heterogeneity among these disorders 
is poorly understood. In theory, this heterogeneity could arise from a disproportionate effect of 
disease and aging related mechanisms on the various isoforms of tau. Here, we examined 
whether known missense mutations in tau gene could differentially affect the properties related 
to both the aggregation and normal function of tau isoforms in vitro. 
 A great majority of tau mutations linked to neurodegenerative diseases are missense point 
mutations, centered around the microtubule stabilizing region, but mutations have been reported 
in the far N-terminal and C-terminal regions of tau as well (70,139).To further examine whether 
the observed effects on tau isoforms would be influenced by the location of the mutation in tau 
primary sequence, mutations were selected from the N-terminal region (R5L), the microtubule 
stabilizing region (P301L) and the C-terminal region (R406W).  
Upon examining the effects of these mutations on in vitro aggregation of 4R isoforms of tau, we 
found that there are subtle but significant differences in how each mutation affected the 
aggregation of a particular tau isoform. While there were disproportionate effects on the overall 
extent of aggregation, the effects on the kinetics of aggregation were more striking. An 
interesting pattern emerged when comparing the rate of aggregation of single mutant in different 
N-terminal variants of tau. The rate of aggregation of the 0N isoform was found to be higher than 
the rate of aggregation for the 2N and 1N isoforms for all three mutants (Figure 23). Thus, the 
removal of N-terminal inserts caused all three mutants to aggregate at an increased rate. In 
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addition, the rate of P301L aggregation was increased in the 1N isoform as compared to the 2N 
isoform. Similar trends can also be seen in both the lag phase and the rate of polymerization of 
the 0N compared to the 2N and 1N wild-type proteins, although the differences are minor and 
not statistically significant under the conditions of the study. Overall, mutants exacerbated these 
possible differences between isoforms. In addition, it can be seen from this comparison that the 
effect of removal of the second N-terminal insert (exon 2) is bigger than the effect of removal of 
the first N-terminal insert (exon 3) on the parameters of kinetics with kinetics of aggregation of 
2N isoform more similar to the 1N isoform and different from the 0N isoform. Overall, the 
observed effects of mutants on 4R tau isoforms seem to be disproportionately more in the 0N4R 
backbone. All three mutants tested in this study consistently had a greater impact on the in vitro 
aggregation properties of the 0N4R isoform as compared to the 1N or 2N isoforms. 
The effect on MT assembly by these mutants were also isoform specific. R5L mutation affected 
the MT assembly induction of 0N4R isoform but did not influence the MT assembly induction 
by the 1N and 2N tau isoforms (Figure 20). P301L and R406W affected all three isoforms but 
the effect was again found to be disproportionate. For example, P301L reduced both the 
maximum amount of MT polymerization and rate of MT polymerization for the 2N and 1N 
isoform but it only affected the maximum amount of MT polymerization for the 0N isoform 
compared to the respective wild-type proteins (Figure 21). In a similar manner, microtubules 
polymerized at a lower rate with the total extent and the nucleation rate (lag phase) of MT 
polymerization remaining unchanged in presence R406W in 2N isoform in comparison to the 
WT 2N isoform (Figure 22). However, R406W only affected the nucleation phase of MT 
polymerization without affecting the total amount or the rate of MT polymerization in presence 
of 0N isoform with R406W mutation compared to the WT.  
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Although for MT stabilization, there is no discernable pattern observed here for R5L and 
R406W, the defect in MT assembly caused by P301L seems to diminish with removal of each N-
terminal exons. The rate of MT polymerization improves as the N-terminal exons are removed in 
the 4R tau isoforms with P301L mutation. This observation points towards a role of N-terminal 
region of tau in MT stabilization. This region of tau is classically not thought to be involved in 
tau’s interaction with microtubules. A possible explanation of the P301L MT assembly data can 
come from the acidic nature of the residues in exon 2 and exon 3 and a possible conformational 
change introduced by the P301L mutation into the global hairpin structure of tau. In the global 
hairpin structure of tau, long-range interactions can exist between the N-terminal region of tau 
and the MT stabilizing region. Also, in such a structure, the C-terminus is also thought to fold 
over to make long range contact with both the N-terminus as well as the MT stabilizing region. 
P301L could alter these interactions such that the N-terminal is brought closer to the MT 
stabilizing region for all three 4R isoforms. In this case, when both exon 2 and 3 are present, the 
negatively charged residues in exon 2 and 3 could interact with the positively charged residues in 
the MT assembly region. Thus, making the MTBR less available to interact with the acidic 
surface of microtubules. In such situation, the more acidic the N-terminal region is, the more 
favorable would be its interaction with the MT stabilizing region rich in positively charged 
residues, and more would be the MT stabilization defects. Consequently, the 0N isoform without 
the acidic N-terminal residues would have a better MT stabilizing ability than the 1N and 2N 
isoforms as was observed with the 4R tau isoforms with the P301L mutation. In agreement with 
this model, a small difference between the MT stabilizing ability of WT 4R isoforms of tau can 
also be detected under the conditions of this study (Figure 24). The rate of MT polymerization 
was found to be slightly better and the lag phase was shorter in presence of the 0N4R wild-type 
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isoform compared to 1N and 2N4R wild-type proteins. Another supporting argument comes 
from the recently published data where the N-terminally truncated forms of tau display stronger 
interactions with the microtubules (59). Further, this pulling down of the N-terminal region 
closer to the MT stabilizing region (tightening of the hairpin) is also thought to be favorable for 
aggregation and in line with this, P301L increases the amount of aggregation of all three 4R 
isoforms. Similar pattern was also detected for two other MT stabilizing region mutations, S320F 
and S352L (data not shown). For both these mutations, the MT assembly was found to be better 
in presence of the 0N4R isoforms compared to the 1N and 2N4R tau isoforms. Although this 
model fits our data the best, without any structural evidence, other possibilities cannot be 
excluded and future studies would help deduce more concrete answers. 
Overall, through this study, we found out that the FTDP-17 mutants can have disproportionate 
effects on both the aggregation propensity as well as the microtubule stabilizing properties of tau 
isoforms. Some of the observed affects are rather subtle but still statistically significant. Whether 
or not these differences can elicit phenotypic differences in vivo, would need to be tested. 
Nonetheless, our data favors the idea that vulnerability of tau isoforms to the disease related 





Figure 13: Polymerization of wild-type and FTDP-17 mutants in 4R isoforms of tau measured by 
Thioflavin S fluorescence and laser light scattering: 2 µM protein was incubated with 75 µM ARA at 25 
°C over-night. The final extent of polymerization was measured using Thioflavin S fluorescence (A, C, E) 
and right-angle laser light scattering (B, D, F). Each bar represents the averaged data from three 
independent experiments ± SD. Stars represent the level of significance calculated using Student’s 
unpaired t-tests, comparing each mutant to the respective wild-type isoform. (*), p < 0.05; (**), p < 0.01; 





Figure 14: Polymerization kinetics of WT and R5L tau in 4R isoforms: A), B), C) Polymerization of 2 
µM protein was initiated using 75 µM ARA at time zero and monitored using right-angle laser light 
scattering at specific intervals until a steady-state was reached. The error bars represent SD from three 
independent trials. Each trace represents the average fit of three trials to the Gompertz equation further 
used to calculate D) maximum polymerization, E) Lag time before polymerization and F) rate of 
polymerization (kapp). Stars represent the level of significance calculated using Student’s unpaired t-tests, 
comparing parameters for the mutant to the respective wild-type isoform. (*), p < 0.05; (**), p < 0.01; 













Figure 15: Polymerization kinetics of WT and P301L tau in 4R isoforms: A), B), C) Polymerization of 2 
µM protein was initiated using 75 µM ARA at time zero and monitored using right-angle laser light 
scattering at specific intervals until a steady-state was reached. The error bars represent SD from three 
independent trials. Each trace represents the average fit of three trials to the Gompertz equation further 
used to calculate D) maximum polymerization, E) Lag time before polymerization and F) rate of 
polymerization (kapp). Stars represent the level of significance calculated using Student’s unpaired t-tests, 
comparing parameters for the mutant to the respective wild-type isoform. (*), p < 0.05; (**), p < 0.01; 










Figure 16: Polymerization kinetics of WT and R406W tau in 4R isoforms: A), B), C) Polymerization of 2 
µM protein was initiated using 75 µM ARA at time zero and monitored using right-angle laser light 
scattering at specific intervals until a steady-state was reached. The error bars represent SD from three 
independent trials. Each trace represents the average fit of three trials to the Gompertz equation further 
used to calculate D) maximum polymerization, E) Lag time before polymerization and F) rate of 
polymerization (kapp). Stars represent the level of significance calculated using Student’s unpaired t-tests, 
comparing parameters for the mutant to the respective wild-type isoform. (*), p < 0.05; (**), p < 0.01; 








Figure 17: Electron micrographs of WT and mutant tau in 4R isoforms. 2 µM protein was polymerized 
using 75 µM ARA overnight at 25 °C and deposited on copper grids. Images were collected at 3600x 




Figure 18: Quantitation of tau polymerization from electron micrographs (Frequency distribution of tau 
filaments for WT and FTDP-17 mutants in 4R isoforms of tau). Filament lengths were measured and 
placed into bins at 100 nm intervals. Length within each bin was summed and plotted as a fraction of the 
total length from all bins (y-axis) against the bin center value (x-axis). Error bars represent data from 
three independent trials. For each trial, quantified data from 5 separate images were pooled together and 





Figure 19: Quantitation of tau polymerization from electron micrographs. Error bars represent data from 
three independent trials. For each trial, quantified data from 5 separate images were pooled together to 
obtain one data point. One way ANOVA with Newman-Keuls Multiple Comparison Test was used to 
determine the statistical significance of data. Stars represent the level of significance of difference 









Figure 20: Microtubule assembly stabilization by WT and R5L tau protein. WT and R5L tau in (A) 
2N4R, (B) 1N4R and (C) 0N4R isoforms were incubated with tubulin. Polymerization of tubulin was 
measured using a fluorescence assay as described in experimental procedures. Data were plotted as 
fluorescence (arbitrary units, y-axis) vs. time (minutes, x-axis) and fit to the Gompertz equation to obtain 
the parameters describing these curves such as D) Maximum amount of tubulin polymerization detected, 
E) the rate of microtubule polymerization and F) the lag time before microtubule polymerization is 
detectable. The data presented here is the obtained by three independent trials and presented as ± SD. 
Stars represent the level of significance calculated using Student’s unpaired t-tests, comparing parameters 










Figure 21: Microtubule assembly stabilization by WT and P301L tau protein. WT and P301L tau in (A) 
2N4R, (B) 1N4R and (C) 0N4R isoforms were incubated with tubulin. Polymerization of tubulin was 
measured using a fluorescence assay as described in experimental procedures. Data were plotted as 
fluorescence (arbitrary units, y-axis) vs. time (minutes, x-axis) and fit to the Gompertz equation to obtain 
the parameters describing these curves such as D) Maximum amount of tubulin polymerization detected, 
E) the rate of microtubule polymerization and F) the lag time before microtubule polymerization is 
detectable. The data presented here is the obtained by three independent trials and presented as ± SD. 
Stars represent the level of significance calculated using Student’s unpaired t-tests, comparing parameters 












Figure 22: Microtubule assembly stabilization by WT and R406W tau protein. WT and R406W tau in 
(A) 2N4R, (B) 1N4R and (C) 0N4R isoforms were incubated with tubulin. Polymerization of tubulin was 
measured using a fluorescence assay as described in experimental procedures. Data were plotted as 
fluorescence (arbitrary units, y-axis) vs. time (minutes, x-axis) and fit to the Gompertz equation to obtain 
the parameters describing these curves such as D) Maximum amount of tubulin polymerization detected, 
E) the rate of microtubule polymerization and F) the lag time before microtubule polymerization is 
detectable. The data presented here is the obtained by three independent trials and presented as ± SD. 
Stars represent the level of significance calculated using Student’s unpaired t-tests, comparing parameters 







Figure 23: Comparison of kinetics between isoforms. One way ANOVA with Newman-Keuls Multiple 
Comparison Test was used to determine the statistical significance of data. Stars represent the level of 
significance of difference between various 4R isoforms wild-types or FTDP-17 mutants. (*), p < 0.05; 




Figure 24: MT assembly wild-type 4R tau isoforms. Data from nine replicates for wild-type proteins is 
pooled together. One way ANOVA with Newman-Keuls Multiple Comparison Test was used to 
determine the statistical significance of data. Stars represent the level of significance of difference 
































Chapter 4: Conclusions and future directions 
Tauopathies, including Alzheimer’s disease, are progressive neurodegenerative disorders 
characterized by symptoms such as cognitive deficits, decline in memory, behavioral alterations 
and language difficulties. These disorders pose a huge health challenge for the aging population 
and are predicted to become more prevalent as the average human life-span increases. Currently, 
there are no known therapies that can slow the progression of these disorders. Although the 
underlying causative mechanisms still need to be elucidated, prevalence of intracellular 
neurofibrillary pathology composed by misfolded and aggregated tau is a major pathological 
hallmark for these diseases. Before effective therapies can be developed to prevent the 
aggregation and potential toxicity of tau aggregation, a better mechanistic understanding of 
factors influencing this process is warranted. One of the factors complicating our understanding 
of tau biology is the existence of six different isoforms of tau. The expression of these tau 
isoforms is tightly regulated in the brain, although the functional relevance of this tightly 
controlled expression ratio is not understood. Also, a lack of existence of any tertiary structure of 
tau has prevented researchers from understanding any possible conformational differences 
between these tau isoforms. Due to these reasons, understanding the differences between these 
isoforms has not been of priority. Often, any possible differences between these isoforms have 
been ignored and these isoforms of tau have been considered equivalent and interchangeable for 
the design of many studies. Contrary to this, there is evidence that points towards the differences 
between these isoforms of tau. For example, an imbalance of their expression ratio in the brain 
has been implicated for several tauopathies. In certain FTDP-17 cases, only specific isoforms of 
tau were found to be deposited as aggregates suggesting that these mutants may affect certain tau 
isoforms disproportionately. Therefore, there is a need for studies aimed towards understanding 
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the differences between tau isoforms and how any disease related mechanisms might affect them 
in comparison to each other. One of the ways employed to learn about tau aggregation is by 
inducing the aggregation of recombinant tau using inducer molecules such as arachidonic acid. 
Using this technique, one can determine if certain conditions can alter the extent or rate of tau 
aggregation. Further, it can also be determined if a certain condition can change the physical 
properties of tau filaments like their appearance, length or number. All these indicators together 
can help decipher the possible modulators of tau’s conformation and aggregation which can 
further be tested in in vivo model systems. This methodology has been previously employed to 
study the aggregation of the 2N4R isoform of tau successfully. However, attempts to employ this 
technique to study the aggregation of other isoforms of tau has been difficult as these isoforms 
have failed to aggregate in a reliable and reproducible manner (discussed in chapter 2). This has 
prevented us from reliably deducing factors that can modulate the aggregation of these isoforms 
of tau in an effort to gain a mechanistic understanding of this process. It has also made it difficult 
to test any small molecule inhibitors of tau aggregation as a part of the long-term goal of finding 
effective therapies against tauopathies.  
The first part of this dissertation is focused on identifying the challenges associated with 
aggregation of tau isoforms, understanding the underlying cause of it and using that knowledge 
for optimizing the aggregation protocol in order to obtain a more robust method for in vitro 
aggregation of various tau isoforms. We discovered that the highly acidic nature of exon 2 and 3 
causes major behavioral changes in tau isoforms. Thus, the asymmetric distribution of charges 
could be widening the differences between the tau isoforms as removal of the N-terminal exons 
specifically would lead to loss of acidic residues. For the purposes of in vitro aggregation, these 
differences can largely be overcome by using higher ionic strength conditions and we were 
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successfully able to optimize the protocol to be able to polymerize all the 4R tau isoforms into 
filamentous aggregates. 
This enabled the further study of the effects of FTDP-17 mutants on various 4R isoforms of tau. 
Looking at the effects of mutants on both the aggregation and microtubule stabilization 
properties of tau isoforms, we found out that mutations were not equivalent in different isoform 
backbones. Some mutants either preferentially affected a certain tau isoform or the level of the 
effect differed between the isoforms. This study reinforces the notion that the choice of isoform 
can have significant implications on the experimental results obtained in a study. Further, our 
data also indicates that the P301L mutation might cause tau to adopt a conformation that favors 
its aggregation. A conformational change could have effects beyond aggregation and 
microtubule stabilization properties of tau. Tau is known to have several binding partners and is 
involved in numerous signaling pathways. It can be speculated that the largely disordered nature 
of tau and an ability to alter its conformation could be working in its favor to be able to have 
several different binding partners and perform different cellular functions. A mutation that can 
favor one conformation or can possibly lock tau in one conformation would also have a large 
impact on several cellular pathways independent of protein aggregation. A conformational 
change can also further alter the post-translational modification pattern of tau. Future studies 
such as using FRET can be designed to measure the distances between various regions of tau to 
test the possibility that some FTDP-17 mutants could be in a conformationally different state 
than the wild-type.  
The presented studies have helped us understand the differences between tau and how some 
disease related changes can possibly affect tau isoforms differentially. We also need to follow up 
these studies by investigating additional FTDP-17 mutants as well as other changes in tau like 
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phosphorylation, truncations, or other post-translational modifications in various isoforms of tau.  
It will also be important to investigate the differences in cultured cells or animal models. Overall, 
the ability to reliably conduct the in vitro studies with isoforms of tau has opened a new area of 
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